Neuronal Ceroid Lipofuscinosis

Genetic MONDO:0016295 Pathograph 27 Show in embeddings browser Lysosomal Storage Disease Neurodegenerative Disease

Neuronal ceroid lipofuscinosis (NCL; Batten disease) is a genetically heterogeneous group of lysosomal neurodegenerative disorders that primarily affect children and are characterized by toxic endo-lysosomal storage with abnormal autofluorescent ceroid/lipopigment material, progressive visual and cognitive decline, seizures, myoclonus, and worsening motor dysfunction.

Ask OpenScientist

Ask a research question about Neuronal Ceroid Lipofuscinosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
9
Pathophys.
7
Phenotypes
27
Pathograph
10
Genes
2
Medical Actions
9
Subtypes
4
Datasets
1
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0009745 neuronal ceroid lipofuscinosis 5 Not Yet Curated
skos:narrowMatch MONDO
MONDO:0009745 is_a the MONDO:0016295 anchor of this entry and is defined as its CLN5 subtype (intersection_of RO:0004003 HGNC:2076). This entry curates CLN5 (hgnc:2076) among its genotypes, so the CLN5 child term is covered here. narrowMatch rather than exactMatch because the anchor subsumes the whole CLN series.
◆

Subtypes

9
CLN1 Disease MONDO:0009744
PPT1 hgnc:9325 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in PPT1 (hgnc:9325). hgnc:9325 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Classic infantile neuronal ceroid lipofuscinosis caused by variants in PPT1.
Show evidence (1 reference)
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"In most cases, these are lysosomal proteins, which include enzymes and a soluble protein (encoded by CLN1/PPT1, CLN2/TPP1, CLN5, CLN10/CTSD, CLN13/CTSF)"
Confirms the CLN1 = PPT1 identity this row asserts, in a review of NCL genetics.
CLN2 Disease MONDO:0008769
TPP1 hgnc:2073 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in TPP1 (hgnc:2073). hgnc:2073 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Late-infantile neuronal ceroid lipofuscinosis caused by variants in TPP1.
Show evidence (1 reference)
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"In most cases, these are lysosomal proteins, which include enzymes and a soluble protein (encoded by CLN1/PPT1, CLN2/TPP1, CLN5, CLN10/CTSD, CLN13/CTSF)"
Confirms the CLN2 = TPP1 identity this row asserts.
CLN3 Disease MONDO:0008767
CLN3 hgnc:2074 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CLN3 (hgnc:2074). hgnc:2074 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Juvenile neuronal ceroid lipofuscinosis caused by variants in CLN3.
Show evidence (1 reference)
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"transmembrane proteins (encoded by CLN3, CLN6, CLN7/MFSD8, CLN12/ATP13A2)"
Places CLN3 in the transmembrane rather than the soluble-enzyme class, which is why this subtype is wired to the endomembrane node and CLN1 and CLN2 are wired to the enzyme-deficiency node.
CLN5 Disease MONDO:0009745
CLN5 hgnc:2076 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CLN5 (hgnc:2076). hgnc:2076 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Neuronal ceroid lipofuscinosis 5, caused by biallelic variants in CLN5. The 2015 genetics review cited below classifies CLN5 among the soluble lysosomal proteins rather than the lysosomal enzymes or the transmembrane proteins, which is why this subtype enters the pathograph at the soluble lysosomal enzyme and protein deficiency node. HGNC's current name for the gene, CLN5 lysosomal BMP synthase, assigns it an enzymatic activity the review did not.
Show evidence (2 references)
CGGV:assertion_a522b1d6-5ade-4749-94b8-d5426bbe5961-2021-09-08T023930.981Z SUPPORT Other
"CLN5 | HGNC:2076 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen's Epilepsy Gene Curation Expert Panel classifies the CLN5-neuronal ceroid lipofuscinosis relationship as definitive with autosomal recessive inheritance, which is the gene-disease assertion this row makes.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular..."
Places CLN5 in the soluble-lysosomal-protein class, distinct from both the lysosomal enzymes and the transmembrane proteins, which is the protein-class claim in this row.
CLN6 Disease MONDO:0011144
CLN6 hgnc:2077 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CLN6 (hgnc:2077). hgnc:2077 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
The 6A form of CLN6 disease, caused by biallelic variants in CLN6. CLN6 encodes a transmembrane protein. MONDO records on this term that biallelic CLN6 variants can also cause juvenile or adult-onset disease known as Kufs disease (MONDO:0008768); that adult form is curated in the Adult_Neuronal_Ceroid_Lipofuscinosis entry rather than here.
Show evidence (2 references)
CGGV:assertion_09654b45-6649-4d11-b43e-aeb6d20fb86d-2020-12-01T170000.000Z SUPPORT Other
"CLN6 | HGNC:2077 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen's Epilepsy Gene Curation Expert Panel classifies the CLN6-neuronal ceroid lipofuscinosis relationship as definitive with autosomal recessive inheritance, which is the gene-disease assertion this row makes.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular..."
Places CLN6 among the transmembrane proteins, which is why this subtype is wired to the endomembrane-protein node rather than the enzyme-deficiency node.
CLN7 Disease MONDO:0012588
MFSD8 hgnc:28486 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in MFSD8 (hgnc:28486). hgnc:28486 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Neuronal ceroid lipofuscinosis 7, caused by biallelic variants in MFSD8 (the gene formerly carrying the symbol CLN7). MFSD8 encodes a transmembrane protein. Also curated as its own entry, Neuronal_Ceroid_Lipofuscinosis_7.
Show evidence (2 references)
CGGV:assertion_0f42cb66-5f28-4674-8f5a-76e15880bbfc-2020-12-15T170000.000Z SUPPORT Other
"MFSD8 | HGNC:28486 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen's Epilepsy Gene Curation Expert Panel classifies the MFSD8-neuronal ceroid lipofuscinosis relationship as definitive with autosomal recessive inheritance, which is the gene-disease assertion this row makes.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular..."
Names CLN7/MFSD8 among the transmembrane proteins, the protein class this row assigns it.
CLN8 Disease MONDO:0010830
CLN8 hgnc:2079 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CLN8 (hgnc:2079). hgnc:2079 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Neuronal ceroid lipofuscinosis 8, caused by biallelic variants in CLN8. CLN8 encodes a transmembrane protein of the endoplasmic reticulum and ER-Golgi intermediate compartment.
Show evidence (2 references)
CGGV:assertion_68775ed0-576e-4ee7-90f2-d16329ecd7c1-2020-09-07T220116.243Z SUPPORT Other
"CLN8 | HGNC:2079 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen's Epilepsy Gene Curation Expert Panel classifies the CLN8-neuronal ceroid lipofuscinosis relationship as definitive with autosomal recessive inheritance, which is the gene-disease assertion this row makes.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular..."
Places CLN8 among the transmembrane proteins with different subcellular locations, which is the protein-class claim this row makes.
CLN10 Disease MONDO:0012414
CTSD hgnc:2529 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CTSD (hgnc:2529). hgnc:2529 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Neuronal ceroid lipofuscinosis 10, caused by biallelic variants in CTSD. CTSD encodes cathepsin D, a lysosomal enzyme, so this subtype enters the pathograph at the soluble lysosomal enzyme and protein deficiency node alongside CLN1 and CLN2.
Show evidence (2 references)
CGGV:assertion_d74b1b2a-52a3-4192-b5b4-e4fd46ffc0ba-2020-11-03T180000.000Z SUPPORT Other
"CTSD | HGNC:2529 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen's Epilepsy Gene Curation Expert Panel classifies the CTSD-neuronal ceroid lipofuscinosis relationship as definitive with autosomal recessive inheritance, which is the gene-disease assertion this row makes.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular..."
Places CLN10 among the lysosomal enzymes with CLN1 and CLN2, which is why this subtype shares their pathograph entry point.
CLN11 Disease MONDO:0013866
GRN hgnc:4601 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in GRN (hgnc:4601). hgnc:4601 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Neuronal ceroid lipofuscinosis 11, caused by biallelic variants in GRN. GRN encodes a protein of the secretory pathway rather than a lysosomal enzyme or a transmembrane protein. The NCL phenotype requires biallelic variants: the 2015 review cited below records that heterozygous GRN mutations are instead a major cause of frontotemporal lobar degeneration with TDP-43 inclusions, whose age at onset and neuropathology it describes as markedly different from NCL.
Show evidence (2 references)
CGGV:assertion_49eb0915-acff-423d-a70f-d00d4319d404-2023-01-03T170000.000Z SUPPORT Other
"GRN | HGNC:4601 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen's Epilepsy Gene Curation Expert Panel classifies the GRN-neuronal ceroid lipofuscinosis relationship as definitive with autosomal recessive inheritance, which is the gene-disease assertion this row makes.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular..."
Places CLN11 in the secretory-pathway class, separate from both the lysosomal enzymes and the transmembrane proteins.
⚙

Pathophysiology

9
Soluble Lysosomal Enzyme and Protein Deficiency
A second, biochemically distinct route into the same storage phenotype. CLN1/PPT1, CLN2/TPP1 and CLN10/CTSD encode soluble lysosomal enzymes - a palmitoyl-protein thioesterase, a tripeptidyl peptidase and an aspartic endopeptidase - and CLN5 encodes a soluble lysosomal protein. Loss of these activities removes a degradative step inside the lysosome, unlike the membrane-protein subtypes where the lesion is in compartment identity or transport. The in vivo substrates of these enzymes are incompletely defined, so what specifically fails to be degraded is not settled; what distinguishes this class clinically is that enzyme replacement and gene therapy are tractable for it.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
PPT1 hgnc:9325 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PPT1 (hgnc:9325). hgnc:9325 is a gene from the HUGO Gene Nomenclature Committee. TPP1 hgnc:2073 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TPP1 (hgnc:2073). hgnc:2073 is a gene from the HUGO Gene Nomenclature Committee. CTSD hgnc:2529 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CTSD (hgnc:2529). hgnc:2529 is a gene from the HUGO Gene Nomenclature Committee. CLN5 hgnc:2076 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN5 (hgnc:2076). hgnc:2076 is a gene from the HUGO Gene Nomenclature Committee.
lysosomal protein catabolic process GO:1905146 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased lysosomal protein catabolic process (GO:1905146). GO:1905146 is a biological process from the Gene Ontology.
palmitoyl-protein thioesterase activity (PPT1) GO:0008474 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased palmitoyl-protein thioesterase activity (PPT1), annotated with palmitoyl-(protein) hydrolase activity (GO:0008474). GO:0008474 is a molecular function from the Gene Ontology. tripeptidyl-peptidase activity (TPP1) GO:0008240 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased tripeptidyl-peptidase activity (TPP1), annotated with tripeptidyl-peptidase activity (GO:0008240). GO:0008240 is a molecular function from the Gene Ontology. aspartic-type endopeptidase activity (cathepsin D) GO:0004190 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased aspartic-type endopeptidase activity (cathepsin D), annotated with aspartic-type endopeptidase activity (GO:0004190). GO:0004190 is a molecular function from the Gene Ontology.
lysosome GO:0005764 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves lysosome (GO:0005764). GO:0005764 is a cellular component from the Gene Ontology.
Downstream
Toxic Endo-Lysosomal Storage Loss of a soluble lysosomal hydrolase leaves its substrate undegraded in the lysosome, which is the storage this entry models downstream.
Show evidence (3 references)
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular..."
The classification this node rests on, and the source of the split between this node's gene set and the endomembrane node's.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"The in vivo substrates for the soluble lysosomal enzymes are incompletely defined"
Supports the caveat that the specific undegraded substrate is unknown, which is why this node stops at loss of the degradative step.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"For the enzymatic deficiencies, enzyme replacement and gene therapy are promising approaches that are actively undergoing clinical development"
Supports the clinical distinction this node draws between the enzymatic and non-enzymatic NCL subtypes.
Toxic Endo-Lysosomal Storage
NCL is defined by toxic endo-lysosomal storage that accompanies the genetically heterogeneous lysosomal defects across the disease group.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology. glial cell CL:0000125 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glial cell (CL:0000125). CL:0000125 is a cell type from the Cell Ontology.
lysosomal transport GO:0007041 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated lysosomal transport (GO:0007041). GO:0007041 is a biological process from the Gene Ontology.
Downstream
Autofluorescent Lipopigment Accumulation Toxic endo-lysosomal storage is reflected pathologically by abnormal autofluorescent storage material in neural tissue.
Progressive Neurodegeneration Toxic endo-lysosomal storage is modeled as part of the inherited lysosomal storage disease process that drives progressive neurodegeneration across NCLs.
Show evidence (1 reference)
PMID:35359645 SUPPORT Human Clinical
"These are genetic diseases associated with the formation of toxic endo-lysosomal storage."
This review identifies toxic endo-lysosomal storage as a core mechanistic feature of childhood NCL.
CLN Endomembrane Protein Dysfunction
NCL-causing genes encode proteins distributed across the endomembrane system, and convergent dysfunction of this intracellular network is thought to underlie the shared clinical manifestations across subtypes. This node carries the membrane-associated half of that set: the transmembrane proteins CLN3, CLN6, CLN7/MFSD8 and CLN8 - of which CLN6 and CLN8 sit in the endoplasmic reticulum rather than the lysosome - together with progranulin (CLN11/GRN), which resides in secretory-pathway compartments. Their primary functions in these compartments are largely unresolved, so the shared downstream storage phenotype is better established than the individual routes to it.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
CLN3 hgnc:2074 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN3 (hgnc:2074). hgnc:2074 is a gene from the HUGO Gene Nomenclature Committee. CLN6 hgnc:2077 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN6 (hgnc:2077). hgnc:2077 is a gene from the HUGO Gene Nomenclature Committee. CLN8 hgnc:2079 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN8 (hgnc:2079). hgnc:2079 is a gene from the HUGO Gene Nomenclature Committee. MFSD8 hgnc:28486 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves MFSD8 (hgnc:28486). hgnc:28486 is a gene from the HUGO Gene Nomenclature Committee. GRN hgnc:4601 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GRN (hgnc:4601). hgnc:4601 is a gene from the HUGO Gene Nomenclature Committee.
lysosomal transport GO:0007041 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated lysosomal transport (GO:0007041). GO:0007041 is a biological process from the Gene Ontology.
Downstream
Toxic Endo-Lysosomal Storage Pathogenic CLN-gene disruption of endomembrane and lysosomal processes is modeled upstream of the shared toxic endo-lysosomal storage phenotype.
Autophagy Dysregulation Disrupted CLN/endolysosomal function has far-ranging cellular effects that include autophagy disruption.
Synaptic Dysfunction CLN-gene disruption of the endolysosomal network also perturbs synaptic function, providing a route to seizures and myoclonus.
Show evidence (4 references)
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"However, the transmembrane proteins CLN6 and CLN8 both localize to the endoplasmic reticulum (ER), and progranulin, encoded by CLN11/GRN, is demonstrated to reside in compartments in the secretory pathway"
Sources the gene set bound to this node and the two qualifications its description makes about where those proteins actually sit.
PMID:26026925 SUPPORT REVIEW SYNTHESIS Other
"knowledge regarding the primary functions of the membrane proteins in these compartments largely remains unresolved"
Supports the description's closing caveat that the individual routes from these membrane proteins to storage are not established.
PMID:37022340 SUPPORT Other
"Ceroid lipofuscinosis neuronal (CLN) genes encode 13 proteins that localize throughout the endomembrane system to regulate a variety of cellular processes."
This review places CLN proteins in a shared endomembrane network that regulates multiple intracellular processes relevant to NCL pathogenesis.
+ 1 more reference
Autofluorescent Lipopigment Accumulation
NCL tissue pathology includes lysosomal accumulation of abnormal autofluorescent storage material, with ultrastructural fingerprint, curvilinear, and granular osmiophilic deposits in affected tissues.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
lysosomal transport GO:0007041 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated lysosomal transport (GO:0007041). GO:0007041 is a biological process from the Gene Ontology.
Downstream
Autofluorescent ceroid lipopigment storage The lysosomal lipopigment storage process is measured pathologically as increased autofluorescent ceroid/lipopigment storage material.
Progressive Neurodegeneration Accumulated lysosomal storage material accompanies the progressive neurodegenerative course of NCL.
Retinal Degeneration Storage disease progression includes retinal degeneration, explaining the prominent visual decline in many NCL subtypes.
Show evidence (2 references)
PMID:25270050 SUPPORT Human Clinical
"Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
Supports abnormal autofluorescent lysosomal material as a defining NCL storage pathology.
PMID:25270050 SUPPORT Human Clinical
"Ultrastructural studies of brain and rectal mucosa disclosed accumulation of storage material in various patterns including fingerprint, curvilinear, and granular osmiophilic deposits consistent with the diagnosis of NCL."
Human tissue ultrastructure documents the characteristic storage material patterns used to diagnose NCL.
Autophagy Dysregulation
Impaired autophagic handling is a recurring component of NCL cellular pathology and contributes to progressive neuronal dysfunction.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
autophagy GO:0006914 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated autophagy (GO:0006914). GO:0006914 is a biological process from the Gene Ontology.
Downstream
Progressive Neurodegeneration Chronic autophagy dysfunction contributes to downstream neuronal degeneration in NCL.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"We describe the large variety of experimental models which have aided this research, as well as the most recent technological developments which have shed light on the main mechanisms involved in the cellular pathology, such as apoptosis and autophagy."
This review identifies autophagy as a central cellular pathology mechanism in childhood NCL.
Apoptotic Signaling
Apoptosis is another recurring component of NCL cellular pathology and likely contributes to neuronal loss.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Progressive Neurodegeneration Pathologic apoptotic signaling contributes to downstream neuronal loss and disease progression.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"We describe the large variety of experimental models which have aided this research, as well as the most recent technological developments which have shed light on the main mechanisms involved in the cellular pathology, such as apoptosis and autophagy."
This review identifies apoptosis as a core mechanistic component of NCL cellular pathology.
Synaptic Dysfunction
Endolysosomal disruption in NCL affects synaptic vesicle and synaptic transmission pathways, contributing to epileptic and myoclonic manifestations.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
synaptic vesicle cycle GO:0099504 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated synaptic vesicle cycle (GO:0099504). GO:0099504 is a biological process from the Gene Ontology. chemical synaptic transmission GO:0007268 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated chemical synaptic transmission (GO:0007268). GO:0007268 is a biological process from the Gene Ontology.
Downstream
Seizures Synaptic dysfunction provides a mechanistic route from NCL cellular pathology to epileptic seizures.
Myoclonus Synaptic dysfunction is modeled as contributing to myoclonus in late-infantile NCL presentations.
Show evidence (1 reference)
PMID:31678162 SUPPORT Other
"NCL mutations have far-ranging effects on cellular functions including autophagy and synaptic dysfunction."
Supports synaptic dysfunction as a downstream cellular function affected by NCL mutations.
Glial Cell Activation
Glial cells are affected in NCL and can actively contribute to disease progression, adding a non-neuronal component to the neurodegenerative cascade.
glial cell CL:0000125 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves glial cell (CL:0000125). CL:0000125 is a cell type from the Cell Ontology.
glial cell activation GO:0061900 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased glial cell activation (GO:0061900). GO:0061900 is a biological process from the Gene Ontology.
Downstream
Progressive Neurodegeneration Activated or adversely affected glial cells contribute to the progressive neurodegenerative cascade.
Show evidence (1 reference)
PMID:31678162 SUPPORT Other
"glial cells to be adversely affected and actively contribute to disease progression."
This pathomechanism review supports glial involvement as an active contributor to NCL progression.
Progressive Neurodegeneration
Mutations in CLN genes ultimately drive a shared neurodegenerative disease process across NCL subtypes.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Retinal Degeneration The neurodegenerative storage process affects the retina, producing retinal degeneration upstream of visual impairment.
Visual Impairment Progressive neurodegeneration contributes to the characteristic loss of vision in NCL.
Cognitive Impairment Ongoing neurodegeneration drives progressive cognitive deterioration.
Seizures Progressive neuronal disease contributes to epileptic seizures in NCL.
Developmental Regression Childhood-onset neurodegeneration leads to loss of previously acquired developmental function.
Motor Deterioration Progressive neurodegeneration produces loss of motor function across childhood-onset NCL presentations.
Show evidence (1 reference)
PMID:37022340 SUPPORT Human Clinical
"In humans, mutations in CLN genes cause a devastating form of neurodegeneration called neuronal ceroid lipofuscinosis (NCL), commonly known as Batten disease."
This review directly identifies NCL as a devastating form of neurodegeneration.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Neuronal Ceroid Lipofuscinosis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Eye 2
Visual Impairment HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35628533 SUPPORT Human Clinical
"Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
This review directly identifies progressive vision loss as a common NCL symptom.
Retinal Degeneration HP:0000546 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Retinal degeneration (HP:0000546). HP:0000546 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:25270050 SUPPORT Human Clinical
"progressive retinal degeneration"
The human MFSD8 family report directly documents progressive retinal degeneration in affected NCL patients.
Nervous System 5
Cognitive Impairment HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive impairment (HP:0100543). HP:0100543 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35628533 SUPPORT Human Clinical
"Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
The abstract identifies progressive mental deterioration as a common NCL manifestation, supporting progressive cognitive impairment.
Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35628533 SUPPORT Human Clinical
"Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
This review directly lists epileptic seizures among the common symptoms of NCL.
Developmental Regression HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Developmental regression (HP:0002376). HP:0002376 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35628533 SUPPORT Human Clinical
"Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
Although the review does not use the phrase developmental regression directly, progressive mental and motor deterioration in a childhood-onset neurodegenerative disorder partially supports loss of acquired developmental function.
Motor Deterioration HP:0002333 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor deterioration (HP:0002333). HP:0002333 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17564970 SUPPORT Human Clinical
"including age at onset from 2 to 7 years, epileptic seizures, psychomotor deterioration, myoclonus, loss of vision, and premature death."
Human late-infantile NCL cases list psychomotor deterioration, supporting progressive motor deterioration.
Myoclonus HP:0001336 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myoclonus (HP:0001336). HP:0001336 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17564970 SUPPORT Human Clinical
"including age at onset from 2 to 7 years, epileptic seizures, psychomotor deterioration, myoclonus, loss of vision, and premature death."
Human late-infantile NCL cases explicitly include myoclonus.
🧬

Genetic Associations

10
CLN Genes (Pathogenic Mutations)
Show evidence (1 reference)
PMID:35628533 SUPPORT Human Clinical
"To date, 13 autosomal recessive gene variants, as well as one autosomal dominant gene variant, of NCL have been described."
This review summarizes the marked genetic heterogeneity of NCL across multiple causative CLN loci.
CLN3 (Pathogenic Variants)
Gene: CLN3 hgnc:2074 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CLN3 (hgnc:2074). hgnc:2074 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_6be652b4-092f-4d1c-9606-4dfeb689c4b9-2023-04-04T040000.000Z SUPPORT Other
"CLN3 | HGNC:2074 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the CLN3-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
CLN5 (Pathogenic Variants)
Gene: CLN5 hgnc:2076 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CLN5 (hgnc:2076). hgnc:2076 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_a522b1d6-5ade-4749-94b8-d5426bbe5961-2021-09-08T023930.981Z SUPPORT Other
"CLN5 | HGNC:2076 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the CLN5-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
CLN6 (Pathogenic Variants)
Gene: CLN6 hgnc:2077 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CLN6 (hgnc:2077). hgnc:2077 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_09654b45-6649-4d11-b43e-aeb6d20fb86d-2020-12-01T170000.000Z SUPPORT Other
"CLN6 | HGNC:2077 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the CLN6-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
CLN8 (Pathogenic Variants)
Gene: CLN8 hgnc:2079 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CLN8 (hgnc:2079). hgnc:2079 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_68775ed0-576e-4ee7-90f2-d16329ecd7c1-2020-09-07T220116.243Z SUPPORT Other
"CLN8 | HGNC:2079 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the CLN8-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
CTSD (Pathogenic Variants)
Gene: CTSD hgnc:2529 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CTSD (hgnc:2529). hgnc:2529 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_d74b1b2a-52a3-4192-b5b4-e4fd46ffc0ba-2020-11-03T180000.000Z SUPPORT Other
"CTSD | HGNC:2529 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the CTSD-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
GRN (Pathogenic Variants)
Gene: GRN hgnc:4601 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GRN (hgnc:4601). hgnc:4601 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_49eb0915-acff-423d-a70f-d00d4319d404-2023-01-03T170000.000Z SUPPORT Other
"GRN | HGNC:4601 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the GRN-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
MFSD8 (Pathogenic Variants)
Gene: MFSD8 hgnc:28486 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MFSD8 (hgnc:28486). hgnc:28486 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_0f42cb66-5f28-4674-8f5a-76e15880bbfc-2020-12-15T170000.000Z SUPPORT Other
"MFSD8 | HGNC:28486 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the MFSD8-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
PPT1 (Pathogenic Variants)
Gene: PPT1 hgnc:9325 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PPT1 (hgnc:9325). hgnc:9325 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_ae7ebc05-9401-4932-afe2-a80e0d31e12f-2024-06-10T190000.000Z SUPPORT Other
"PPT1 | HGNC:9325 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the PPT1-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
TPP1 (Pathogenic Variants)
Gene: TPP1 hgnc:2073 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TPP1 (hgnc:2073). hgnc:2073 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive
Show evidence (1 reference)
CGGV:assertion_9b2f3b20-fb9a-4b5e-ad8e-e03be5ebb8e5-2020-09-26T005342.102Z SUPPORT Other
"TPP1 | HGNC:2073 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
ClinGen classifies the TPP1-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
💊

Medical Actions

2
Cerliponase Alfa
Action: enzyme replacement therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is enzyme replacement therapy, annotated with Protein Replacement Therapy (NCIT:C16221). NCIT:C16221 is a clinical intervention from the NCI Thesaurus. Ontology label: Protein Replacement Therapy NCIT:C16221
Enzyme replacement therapy used in CLN2 disease that slows decline in motor and language function.
Mechanism Target:
INHIBITS Progressive Neurodegeneration — In CLN2 disease, intracerebroventricular cerliponase alfa slows motor and language decline, so it is modeled as inhibiting downstream progressive neurodegeneration in that subtype rather than as a cure for all NCL forms.
Show evidence (1 reference)
PMID:31884868 SUPPORT Human Clinical
"Treatment with intracerebroventricular cerliponase alfa resulted in slower decline of motor and language functions compared with natural history controls."
Clinical evidence in CLN2 supports cerliponase alfa as a disease-targeted therapy that slows functional decline.
Show evidence (2 references)
PMID:31884868 SUPPORT Human Clinical
"Treatment with intracerebroventricular cerliponase alfa resulted in slower decline of motor and language functions compared with natural history controls."
This review summarizes clinical evidence that cerliponase alfa slows functional decline in CLN2 disease.
PMID:31884868 SUPPORT Human Clinical
"Cerliponase alfa is the first therapy for neuronal ceroid lipofuscinosis type 2 that targets the disease etiology."
This identifies cerliponase alfa as an etiologically targeted treatment for the CLN2 subtype of NCL.
Supportive Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Palliative and symptomatic management remains the main treatment approach for most NCL subtypes.
Show evidence (1 reference)
PMID:35359645 SUPPORT Human Clinical
"Lastly, we show the importance of palliative care and symptomatic treatments which are still the main therapeutic interventions."
This review makes clear that supportive and symptomatic care remains the main intervention for most NCL forms.
🔬

Biochemical Markers

1
Autofluorescent ceroid lipopigment storage (INCREASED)
Context: NCL is defined pathologically by abnormal autofluorescent lysosomal storage material. No specific local CHEBI or NCIT term was found for ceroid lipofuscin, so this readout is represented without a forced biomarker term.
Pathograph Readouts
Readout Of Autofluorescent Lipopigment Accumulation Positive Diagnostic
Increased autofluorescent storage material reports the core lysosomal lipopigment accumulation node.
Show evidence (1 reference)
PMID:25270050 SUPPORT Human Clinical
"Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
Human NCL evidence defines the storage lesion as lysosomal accumulation of abnormal autofluorescent material.
Show evidence (1 reference)
PMID:25270050 SUPPORT Human Clinical
"Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
Supports autofluorescent lysosomal storage material as the diagnostic biochemical/pathologic readout for the NCL group.
📊

Related Datasets

4
Synapse alterations precede neuronal damage and storage pathology in a human cerebral organoid model of CLN3-Juvenile Neuronal Ceroid Lipofuscinosis geo:GSE137420
We developed an invitro model for Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) using isogenic CLN3 mutated human iPS cell lines and performed transcriptomic profiling of brain organoids derived from these lines to identify transcriptomic changes in the early developing brain model.
human BULK RNA SEQ n=12
PMID:31888773
Identified by GEO DataSets index search for Neuronal Ceroid Lipofuscinosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
Brain transcriptome analysis of a TPP-1 neuronal ceroid lipofuscinosis mouse model as disease progresses geo:GSE173665
We analyzed expression changes in the Tpp1-/- forebrain/midbrain and cerebellum of 1, 2, and 3 mo. mutants compared to strain-related controls RNA-sequencing technology.
mouse BULK RNA SEQ n=36
PMID:34749772
Identified by GEO DataSets index search for Neuronal Ceroid Lipofuscinosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
Recreating pathophysiology of CLN2 disease and demonstrating reversion by TPP1 gene therapy in hiPSCs-derived retinal organoid and retina-on-chip geo:GSE297954
Mutations in tripeptidyl peptidase 1 (TPP1) gene lead to late infantile neuronal ceroid lipofuscinosis CLN2, characterized by lysosomal accumulation of lipofuscins predominantly found in brain and retina. The ocular phenotype is characterized by bilateral outer retinal degeneration that leads to complete vision loss. CLN2 animal models struggle in recapitulating the retinal phenotype observed in patients. Here, we leveraged human induced pluripotent stem cell (hiPSC)-derived retinal organoids (ROs), retinal pigmented epithelial (RPE) cells, and retina-on-chip (RoC) technologies to model CLN2 disease in vitro in patient-specific microphysiological models of the human retina.
human BULK RNA SEQ n=16
PMID:40706588
Identified by GEO DataSets index search for Neuronal Ceroid Lipofuscinosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
iTRAQ8 analysis of control and neuronal ceroid lipofuscinosis human brain samples. massive:MSV000081143
iTRAQ8 analysis of autopsy samples representing brain and cerebrospinal fluid from neuronal ceroid lipofuscinosis patients and controls.
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Neuronal Ceroid Lipofuscinosis"). Retrieved 2026-08-02.
{ }

Source YAML

click to show 
name: Neuronal Ceroid Lipofuscinosis
creation_date: '2026-03-30T18:20:00Z'
description: >
  Neuronal ceroid lipofuscinosis (NCL; Batten disease) is a genetically
  heterogeneous group of lysosomal neurodegenerative disorders that primarily
  affect children and are characterized by toxic endo-lysosomal storage with
  abnormal autofluorescent ceroid/lipopigment material, progressive visual and
  cognitive decline, seizures, myoclonus, and worsening motor dysfunction.
category: Genetic
disease_term:
  preferred_term: neuronal ceroid lipofuscinosis
  term:
    id: MONDO:0016295
    label: neuronal ceroid lipofuscinosis
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0009745
      label: neuronal ceroid lipofuscinosis 5
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >
      MONDO:0009745 is_a the MONDO:0016295 anchor of this entry and is defined as
      its CLN5 subtype (intersection_of RO:0004003 HGNC:2076). This entry curates
      CLN5 (hgnc:2076) among its genotypes, so the CLN5 child term is covered
      here. narrowMatch rather than exactMatch because the anchor subsumes the
      whole CLN series.
synonyms:
- Batten disease
- neuronal ceroid lipofuscinoses
parents:
- Lysosomal Storage Disease
- Neurodegenerative Disease
has_subtypes:
- name: CLN1 Disease
  subtype_term:
    preferred_term: neuronal ceroid lipofuscinosis 1
    term:
      id: MONDO:0009744
      label: neuronal ceroid lipofuscinosis 1
  genes:
  - preferred_term: PPT1
    term:
      id: hgnc:9325
      label: PPT1
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: Classic infantile neuronal ceroid lipofuscinosis caused by variants in PPT1.
  evidence:
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      In most cases, these are lysosomal proteins, which include enzymes and a
      soluble protein (encoded by CLN1/PPT1, CLN2/TPP1, CLN5, CLN10/CTSD,
      CLN13/CTSF)
    explanation: >-
      Confirms the CLN1 = PPT1 identity this row asserts, in a review of NCL
      genetics.
- name: CLN2 Disease
  subtype_term:
    preferred_term: neuronal ceroid lipofuscinosis 2
    term:
      id: MONDO:0008769
      label: neuronal ceroid lipofuscinosis 2
  genes:
  - preferred_term: TPP1
    term:
      id: hgnc:2073
      label: TPP1
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: Late-infantile neuronal ceroid lipofuscinosis caused by variants in TPP1.
  evidence:
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      In most cases, these are lysosomal proteins, which include enzymes and a
      soluble protein (encoded by CLN1/PPT1, CLN2/TPP1, CLN5, CLN10/CTSD,
      CLN13/CTSF)
    explanation: >-
      Confirms the CLN2 = TPP1 identity this row asserts.
- name: CLN3 Disease
  subtype_term:
    preferred_term: neuronal ceroid lipofuscinosis 3
    term:
      id: MONDO:0008767
      label: neuronal ceroid lipofuscinosis 3
  genes:
  - preferred_term: CLN3
    term:
      id: hgnc:2074
      label: CLN3
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: Juvenile neuronal ceroid lipofuscinosis caused by variants in CLN3.
  evidence:
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      transmembrane proteins (encoded by CLN3, CLN6, CLN7/MFSD8, CLN12/ATP13A2)
    explanation: >-
      Places CLN3 in the transmembrane rather than the soluble-enzyme class,
      which is why this subtype is wired to the endomembrane node and CLN1 and
      CLN2 are wired to the enzyme-deficiency node.
- name: CLN5 Disease
  subtype_term:
    preferred_term: neuronal ceroid lipofuscinosis 5
    term:
      id: MONDO:0009745
      label: neuronal ceroid lipofuscinosis 5
  genes:
  - preferred_term: CLN5
    term:
      id: hgnc:2076
      label: CLN5
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: >-
    Neuronal ceroid lipofuscinosis 5, caused by biallelic variants in CLN5. The
    2015 genetics review cited below classifies CLN5 among the soluble lysosomal
    proteins rather than the lysosomal enzymes or the transmembrane proteins,
    which is why this subtype enters the pathograph at the soluble lysosomal
    enzyme and protein deficiency node. HGNC's current name for the gene, CLN5
    lysosomal BMP synthase, assigns it an enzymatic activity the review did not.
  evidence:
  - reference: CGGV:assertion_a522b1d6-5ade-4749-94b8-d5426bbe5961-2021-09-08T023930.981Z
    reference_title: "CLN5 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLN5 | HGNC:2076 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: >-
      ClinGen's Epilepsy Gene Curation Expert Panel classifies the
      CLN5-neuronal ceroid lipofuscinosis relationship as definitive with
      autosomal recessive inheritance, which is the gene-disease assertion this
      row makes.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular locations (CLN3, CLN6, CLN7, CLN8, CLN12)."
    explanation: >-
      Places CLN5 in the soluble-lysosomal-protein class, distinct from both the
      lysosomal enzymes and the transmembrane proteins, which is the protein-class
      claim in this row.
- name: CLN6 Disease
  subtype_term:
    preferred_term: ceroid lipofuscinosis, neuronal, 6A
    term:
      id: MONDO:0011144
      label: ceroid lipofuscinosis, neuronal, 6A
  genes:
  - preferred_term: CLN6
    term:
      id: hgnc:2077
      label: CLN6
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: >-
    The 6A form of CLN6 disease, caused by biallelic variants in CLN6. CLN6
    encodes a transmembrane protein. MONDO records on this term that biallelic
    CLN6 variants can also cause juvenile or adult-onset disease known as Kufs
    disease (MONDO:0008768); that adult form is curated in the
    Adult_Neuronal_Ceroid_Lipofuscinosis entry rather than here.
  evidence:
  - reference: CGGV:assertion_09654b45-6649-4d11-b43e-aeb6d20fb86d-2020-12-01T170000.000Z
    reference_title: "CLN6 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLN6 | HGNC:2077 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: >-
      ClinGen's Epilepsy Gene Curation Expert Panel classifies the
      CLN6-neuronal ceroid lipofuscinosis relationship as definitive with
      autosomal recessive inheritance, which is the gene-disease assertion this
      row makes.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular locations (CLN3, CLN6, CLN7, CLN8, CLN12)."
    explanation: >-
      Places CLN6 among the transmembrane proteins, which is why this subtype is
      wired to the endomembrane-protein node rather than the enzyme-deficiency
      node.
- name: CLN7 Disease
  subtype_term:
    preferred_term: neuronal ceroid lipofuscinosis 7
    term:
      id: MONDO:0012588
      label: neuronal ceroid lipofuscinosis 7
  genes:
  - preferred_term: MFSD8
    term:
      id: hgnc:28486
      label: MFSD8
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: >-
    Neuronal ceroid lipofuscinosis 7, caused by biallelic variants in MFSD8
    (the gene formerly carrying the symbol CLN7). MFSD8 encodes a transmembrane
    protein. Also curated as its own entry, Neuronal_Ceroid_Lipofuscinosis_7.
  evidence:
  - reference: CGGV:assertion_0f42cb66-5f28-4674-8f5a-76e15880bbfc-2020-12-15T170000.000Z
    reference_title: "MFSD8 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MFSD8 | HGNC:28486 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: >-
      ClinGen's Epilepsy Gene Curation Expert Panel classifies the
      MFSD8-neuronal ceroid lipofuscinosis relationship as definitive with
      autosomal recessive inheritance, which is the gene-disease assertion this
      row makes.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular locations (CLN3, CLN6, CLN7, CLN8, CLN12)."
    explanation: >-
      Names CLN7/MFSD8 among the transmembrane proteins, the protein class this
      row assigns it.
- name: CLN8 Disease
  subtype_term:
    preferred_term: neuronal ceroid lipofuscinosis 8
    term:
      id: MONDO:0010830
      label: neuronal ceroid lipofuscinosis 8
  genes:
  - preferred_term: CLN8
    term:
      id: hgnc:2079
      label: CLN8
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: >-
    Neuronal ceroid lipofuscinosis 8, caused by biallelic variants in CLN8.
    CLN8 encodes a transmembrane protein of the endoplasmic reticulum and
    ER-Golgi intermediate compartment.
  evidence:
  - reference: CGGV:assertion_68775ed0-576e-4ee7-90f2-d16329ecd7c1-2020-09-07T220116.243Z
    reference_title: "CLN8 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLN8 | HGNC:2079 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: >-
      ClinGen's Epilepsy Gene Curation Expert Panel classifies the
      CLN8-neuronal ceroid lipofuscinosis relationship as definitive with
      autosomal recessive inheritance, which is the gene-disease assertion this
      row makes.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular locations (CLN3, CLN6, CLN7, CLN8, CLN12)."
    explanation: >-
      Places CLN8 among the transmembrane proteins with different subcellular
      locations, which is the protein-class claim this row makes.
- name: CLN10 Disease
  subtype_term:
    preferred_term: neuronal ceroid lipofuscinosis 10
    term:
      id: MONDO:0012414
      label: neuronal ceroid lipofuscinosis 10
  genes:
  - preferred_term: CTSD
    term:
      id: hgnc:2529
      label: CTSD
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: >-
    Neuronal ceroid lipofuscinosis 10, caused by biallelic variants in CTSD.
    CTSD encodes cathepsin D, a lysosomal enzyme, so this subtype enters the
    pathograph at the soluble lysosomal enzyme and protein deficiency node
    alongside CLN1 and CLN2.
  evidence:
  - reference: CGGV:assertion_d74b1b2a-52a3-4192-b5b4-e4fd46ffc0ba-2020-11-03T180000.000Z
    reference_title: "CTSD / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CTSD | HGNC:2529 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: >-
      ClinGen's Epilepsy Gene Curation Expert Panel classifies the
      CTSD-neuronal ceroid lipofuscinosis relationship as definitive with
      autosomal recessive inheritance, which is the gene-disease assertion this
      row makes.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular locations (CLN3, CLN6, CLN7, CLN8, CLN12)."
    explanation: >-
      Places CLN10 among the lysosomal enzymes with CLN1 and CLN2, which is why
      this subtype shares their pathograph entry point.
- name: CLN11 Disease
  subtype_term:
    preferred_term: neuronal ceroid lipofuscinosis 11
    term:
      id: MONDO:0013866
      label: neuronal ceroid lipofuscinosis 11
  genes:
  - preferred_term: GRN
    term:
      id: hgnc:4601
      label: GRN
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  description: >-
    Neuronal ceroid lipofuscinosis 11, caused by biallelic variants in GRN.
    GRN encodes a protein of the secretory pathway rather than a lysosomal
    enzyme or a transmembrane protein. The NCL phenotype requires biallelic
    variants: the 2015 review cited below records that heterozygous GRN
    mutations are instead a major cause of frontotemporal lobar degeneration
    with TDP-43 inclusions, whose age at onset and neuropathology it describes
    as markedly different from NCL.
  evidence:
  - reference: CGGV:assertion_49eb0915-acff-423d-a70f-d00d4319d404-2023-01-03T170000.000Z
    reference_title: "GRN / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GRN | HGNC:4601 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: >-
      ClinGen's Epilepsy Gene Curation Expert Panel classifies the
      GRN-neuronal ceroid lipofuscinosis relationship as definitive with
      autosomal recessive inheritance, which is the gene-disease assertion this
      row makes.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular locations (CLN3, CLN6, CLN7, CLN8, CLN12)."
    explanation: >-
      Places CLN11 in the secretory-pathway class, separate from both the
      lysosomal enzymes and the transmembrane proteins.
references:
- reference: PMID:20301601
  title: "Neuronal Ceroid Lipofuscinoses Overview."
  tags:
  - GeneReviews
  findings: []
pathophysiology:
- name: Soluble Lysosomal Enzyme and Protein Deficiency
  description: >-
    A second, biochemically distinct route into the same storage phenotype.
    CLN1/PPT1, CLN2/TPP1 and CLN10/CTSD encode soluble lysosomal enzymes - a
    palmitoyl-protein thioesterase, a tripeptidyl peptidase and an aspartic
    endopeptidase - and CLN5 encodes a soluble lysosomal protein. Loss of these
    activities removes a degradative step inside the lysosome, unlike the
    membrane-protein subtypes where the lesion is in compartment identity or
    transport. The in vivo substrates of these enzymes are incompletely
    defined, so what specifically fails to be degraded is not settled; what
    distinguishes this class clinically is that enzyme replacement and gene
    therapy are tractable for it.
  genes:
  - preferred_term: PPT1
    term:
      id: hgnc:9325
      label: PPT1
  - preferred_term: TPP1
    term:
      id: hgnc:2073
      label: TPP1
  - preferred_term: CTSD
    term:
      id: hgnc:2529
      label: CTSD
  - preferred_term: CLN5
    term:
      id: hgnc:2076
      label: CLN5
  molecular_functions:
  - preferred_term: palmitoyl-protein thioesterase activity (PPT1)
    term:
      id: GO:0008474
      label: palmitoyl-(protein) hydrolase activity
    modifier: DECREASED
  - preferred_term: tripeptidyl-peptidase activity (TPP1)
    term:
      id: GO:0008240
      label: tripeptidyl-peptidase activity
    modifier: DECREASED
  - preferred_term: aspartic-type endopeptidase activity (cathepsin D)
    term:
      id: GO:0004190
      label: aspartic-type endopeptidase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: lysosomal protein catabolic process
    term:
      id: GO:1905146
      label: lysosomal protein catabolic process
    modifier: DECREASED
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble
      lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two
      cytoplasmic proteins that also peripherally associate with membranes
      (CLN4, CLN14), and many transmembrane proteins with different subcellular
      locations (CLN3, CLN6, CLN7, CLN8, CLN12).
    explanation: >-
      The classification this node rests on, and the source of the split
      between this node's gene set and the endomembrane node's.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      The in vivo substrates for the soluble lysosomal enzymes are incompletely
      defined
    explanation: >-
      Supports the caveat that the specific undegraded substrate is unknown,
      which is why this node stops at loss of the degradative step.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      For the enzymatic deficiencies, enzyme replacement and gene therapy are
      promising approaches that are actively undergoing clinical development
    explanation: >-
      Supports the clinical distinction this node draws between the enzymatic
      and non-enzymatic NCL subtypes.
  downstream:
  - target: Toxic Endo-Lysosomal Storage
    description: >-
      Loss of a soluble lysosomal hydrolase leaves its substrate undegraded in
      the lysosome, which is the storage this entry models downstream.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Toxic Endo-Lysosomal Storage
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >
    NCL is defined by toxic endo-lysosomal storage that accompanies the
    genetically heterogeneous lysosomal defects across the disease group.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: glial cell
    term:
      id: CL:0000125
      label: glial cell
  biological_processes:
  - preferred_term: lysosomal transport
    modifier: DYSREGULATED
    term:
      id: GO:0007041
      label: lysosomal transport
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These are genetic diseases associated with the formation of toxic endo-lysosomal storage."
    explanation: This review identifies toxic endo-lysosomal storage as a core mechanistic feature of childhood NCL.
  downstream:
  - target: Autofluorescent Lipopigment Accumulation
    description: >
      Toxic endo-lysosomal storage is reflected pathologically by abnormal
      autofluorescent storage material in neural tissue.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25270050
      reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
      explanation: >
        Human NCL cases define the disorder by lysosomal accumulation of
        abnormal autofluorescent material, supporting this storage readout
        downstream of toxic endo-lysosomal storage.
  - target: Progressive Neurodegeneration
    description: >
      Toxic endo-lysosomal storage is modeled as part of the inherited
      lysosomal storage disease process that drives progressive
      neurodegeneration across NCLs.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31678162
      reference_title: "Pathomechanisms in the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >
        The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited
        neurodegenerative lysosomal storage disorders (LSDs)
      explanation: >
        The review defines NCLs as inherited neurodegenerative lysosomal storage
        disorders, supporting an indirect connection from storage pathology to
        the shared neurodegenerative process.
- name: CLN Endomembrane Protein Dysfunction
  description: >
    NCL-causing genes encode proteins distributed across the endomembrane
    system, and convergent dysfunction of this intracellular network is thought
    to underlie the shared clinical manifestations across subtypes. This node
    carries the membrane-associated half of that set: the transmembrane
    proteins CLN3, CLN6, CLN7/MFSD8 and CLN8 - of which CLN6 and CLN8 sit in
    the endoplasmic reticulum rather than the lysosome - together with
    progranulin (CLN11/GRN), which resides in secretory-pathway compartments.
    Their primary functions in these compartments are largely unresolved, so
    the shared downstream storage phenotype is better established than the
    individual routes to it.
  genes:
  - preferred_term: CLN3
    term:
      id: hgnc:2074
      label: CLN3
  - preferred_term: CLN6
    term:
      id: hgnc:2077
      label: CLN6
  - preferred_term: CLN8
    term:
      id: hgnc:2079
      label: CLN8
  - preferred_term: MFSD8
    term:
      id: hgnc:28486
      label: MFSD8
  - preferred_term: GRN
    term:
      id: hgnc:4601
      label: GRN
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: lysosomal transport
    modifier: DYSREGULATED
    term:
      id: GO:0007041
      label: lysosomal transport
  evidence:
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      However, the transmembrane proteins CLN6 and CLN8 both localize to the
      endoplasmic reticulum (ER), and progranulin, encoded by CLN11/GRN, is
      demonstrated to reside in compartments in the secretory pathway
    explanation: >-
      Sources the gene set bound to this node and the two qualifications its
      description makes about where those proteins actually sit.
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: >-
      knowledge regarding the primary functions of the membrane proteins in
      these compartments largely remains unresolved
    explanation: >-
      Supports the description's closing caveat that the individual routes from
      these membrane proteins to storage are not established.
  - reference: PMID:37022340
    reference_title: "Recent insights into the networking of CLN genes and proteins in mammalian cells."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Ceroid lipofuscinosis neuronal (CLN) genes encode 13 proteins that localize throughout the endomembrane system to regulate a variety of cellular processes."
    explanation: This review places CLN proteins in a shared endomembrane network that regulates multiple intracellular processes relevant to NCL pathogenesis.
  - reference: PMID:37022340
    reference_title: "Recent insights into the networking of CLN genes and proteins in mammalian cells."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A growing body of literature supports the networking of CLN genes and proteins within cells, which aligns with the broadly similar cellular and clinical manifestations among the different subtypes of NCL."
    explanation: This supports convergent intracellular CLN protein dysfunction as an explanation for shared manifestations across NCL subtypes.
  downstream:
  - target: Toxic Endo-Lysosomal Storage
    description: >
      Pathogenic CLN-gene disruption of endomembrane and lysosomal processes is
      modeled upstream of the shared toxic endo-lysosomal storage phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37022340
      reference_title: "Recent insights into the networking of CLN genes and proteins in mammalian cells."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        In humans, mutations in CLN genes cause a devastating form of
        neurodegeneration called neuronal ceroid lipofuscinosis (NCL), commonly
        known as Batten disease.
      explanation: >
        This review directly links CLN-gene mutations to the human NCL disease
        group.
    - reference: PMID:31678162
      reference_title: "Pathomechanisms in the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >
        The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited
        neurodegenerative lysosomal storage disorders (LSDs)
      explanation: >
        This review classifies NCLs as lysosomal storage disorders, supporting
        toxic endo-lysosomal storage as the downstream storage phenotype of
        CLN-gene disease.
  - target: Autophagy Dysregulation
    description: >
      Disrupted CLN/endolysosomal function has far-ranging cellular effects
      that include autophagy disruption.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31678162
      reference_title: "Pathomechanisms in the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "NCL mutations have far-ranging effects on cellular functions including autophagy and synaptic dysfunction."
      explanation: >
        This pathomechanism review links NCL mutations to autophagy as one of
        the affected downstream cellular functions.
  - target: Synaptic Dysfunction
    description: >
      CLN-gene disruption of the endolysosomal network also perturbs synaptic
      function, providing a route to seizures and myoclonus.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31678162
      reference_title: "Pathomechanisms in the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "NCL mutations have far-ranging effects on cellular functions including autophagy and synaptic dysfunction."
      explanation: >
        This review explicitly identifies synaptic dysfunction among downstream
        cellular consequences of NCL mutations.
- name: Autofluorescent Lipopigment Accumulation
  description: >
    NCL tissue pathology includes lysosomal accumulation of abnormal
    autofluorescent storage material, with ultrastructural fingerprint,
    curvilinear, and granular osmiophilic deposits in affected tissues.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: lysosomal transport
    modifier: DYSREGULATED
    term:
      id: GO:0007041
      label: lysosomal transport
  evidence:
  - reference: PMID:25270050
    reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
    explanation: >
      Supports abnormal autofluorescent lysosomal material as a defining NCL
      storage pathology.
  - reference: PMID:25270050
    reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ultrastructural studies of brain and rectal mucosa disclosed accumulation of storage material in various patterns including fingerprint, curvilinear, and granular osmiophilic deposits consistent with the diagnosis of NCL."
    explanation: >
      Human tissue ultrastructure documents the characteristic storage material
      patterns used to diagnose NCL.
  downstream:
  - target: Autofluorescent ceroid lipopigment storage
    description: >
      The lysosomal lipopigment storage process is measured pathologically as
      increased autofluorescent ceroid/lipopigment storage material.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25270050
      reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
      explanation: >
        This statement supports the biochemical/pathologic storage readout as
        a direct report of the NCL lysosomal storage lesion.
  - target: Progressive Neurodegeneration
    description: >
      Accumulated lysosomal storage material accompanies the progressive
      neurodegenerative course of NCL.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25270050
      reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
      explanation: >
        The same human evidence defines NCL as a neurodegenerative disorder with
        lysosomal autofluorescent material, supporting the storage-to-neurodegeneration
        connection.
  - target: Retinal Degeneration
    description: >
      Storage disease progression includes retinal degeneration, explaining the
      prominent visual decline in many NCL subtypes.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25270050
      reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "progressive retinal degeneration"
      explanation: >
        The human MFSD8 family report documents progressive retinal degeneration
        as part of the NCL phenotype.
- name: Autophagy Dysregulation
  description: >
    Impaired autophagic handling is a recurring component of NCL cellular
    pathology and contributes to progressive neuronal dysfunction.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: autophagy
    modifier: DYSREGULATED
    term:
      id: GO:0006914
      label: autophagy
  downstream:
  - target: Progressive Neurodegeneration
    description: Chronic autophagy dysfunction contributes to downstream neuronal degeneration in NCL.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35359645
      reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "We describe the large variety of experimental models which have aided this research, as well as the most recent technological developments which have shed light on the main mechanisms involved in the cellular pathology, such as apoptosis and autophagy."
      explanation: This review identifies autophagy as a core cellular pathology mechanism in NCL, partially supporting its contribution to downstream neurodegeneration.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We describe the large variety of experimental models which have aided this research, as well as the most recent technological developments which have shed light on the main mechanisms involved in the cellular pathology, such as apoptosis and autophagy."
    explanation: This review identifies autophagy as a central cellular pathology mechanism in childhood NCL.
- name: Apoptotic Signaling
  description: >
    Apoptosis is another recurring component of NCL cellular pathology and
    likely contributes to neuronal loss.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Progressive Neurodegeneration
    description: Pathologic apoptotic signaling contributes to downstream neuronal loss and disease progression.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35359645
      reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "We describe the large variety of experimental models which have aided this research, as well as the most recent technological developments which have shed light on the main mechanisms involved in the cellular pathology, such as apoptosis and autophagy."
      explanation: This review identifies apoptosis as a core NCL cellular mechanism, partially supporting its role in downstream neurodegeneration.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We describe the large variety of experimental models which have aided this research, as well as the most recent technological developments which have shed light on the main mechanisms involved in the cellular pathology, such as apoptosis and autophagy."
    explanation: This review identifies apoptosis as a core mechanistic component of NCL cellular pathology.
- name: Synaptic Dysfunction
  description: >
    Endolysosomal disruption in NCL affects synaptic vesicle and synaptic
    transmission pathways, contributing to epileptic and myoclonic manifestations.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: synaptic vesicle cycle
    modifier: DYSREGULATED
    term:
      id: GO:0099504
      label: synaptic vesicle cycle
  - preferred_term: chemical synaptic transmission
    modifier: DYSREGULATED
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:31678162
    reference_title: "Pathomechanisms in the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NCL mutations have far-ranging effects on cellular functions including autophagy and synaptic dysfunction."
    explanation: >
      Supports synaptic dysfunction as a downstream cellular function affected
      by NCL mutations.
  downstream:
  - target: Seizures
    description: >
      Synaptic dysfunction provides a mechanistic route from NCL cellular
      pathology to epileptic seizures.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:17564970
      reference_title: "The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "including age at onset from 2 to 7 years, epileptic seizures, psychomotor deterioration, myoclonus, loss of vision, and premature death."
      explanation: >
        Human late-infantile NCL cases list epileptic seizures among core
        manifestations, supporting a downstream seizure edge.
  - target: Myoclonus
    description: >
      Synaptic dysfunction is modeled as contributing to myoclonus in
      late-infantile NCL presentations.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:17564970
      reference_title: "The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "including age at onset from 2 to 7 years, epileptic seizures, psychomotor deterioration, myoclonus, loss of vision, and premature death."
      explanation: >
        The human NCL cohort report explicitly lists myoclonus among
        late-infantile-onset NCL features.
- name: Glial Cell Activation
  description: >
    Glial cells are affected in NCL and can actively contribute to disease
    progression, adding a non-neuronal component to the neurodegenerative
    cascade.
  cell_types:
  - preferred_term: glial cell
    term:
      id: CL:0000125
      label: glial cell
  biological_processes:
  - preferred_term: glial cell activation
    modifier: INCREASED
    term:
      id: GO:0061900
      label: glial cell activation
  evidence:
  - reference: PMID:31678162
    reference_title: "Pathomechanisms in the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "glial cells to be adversely affected and actively contribute to disease progression."
    explanation: >
      This pathomechanism review supports glial involvement as an active
      contributor to NCL progression.
  downstream:
  - target: Progressive Neurodegeneration
    description: >
      Activated or adversely affected glial cells contribute to the progressive
      neurodegenerative cascade.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31678162
      reference_title: "Pathomechanisms in the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "glial cells to be adversely affected and actively contribute to disease progression."
      explanation: >
        The review directly links glial involvement to active contribution to
        NCL disease progression.
- name: Progressive Neurodegeneration
  description: >
    Mutations in CLN genes ultimately drive a shared neurodegenerative disease
    process across NCL subtypes.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Retinal Degeneration
    description: >
      The neurodegenerative storage process affects the retina, producing
      retinal degeneration upstream of visual impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25270050
      reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "progressive retinal degeneration"
      explanation: >
        Human cases document progressive retinal degeneration as part of NCL.
  - target: Visual Impairment
    description: Progressive neurodegeneration contributes to the characteristic loss of vision in NCL.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35628533
      reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
      explanation: This review supports progressive loss of vision as a downstream manifestation of NCL neurodegeneration.
  - target: Cognitive Impairment
    description: Ongoing neurodegeneration drives progressive cognitive deterioration.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35628533
      reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
      explanation: This review supports mental deterioration and dementia as downstream manifestations of the underlying neurodegenerative process.
  - target: Seizures
    description: Progressive neuronal disease contributes to epileptic seizures in NCL.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35628533
      reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
      explanation: This review supports epileptic seizures as a downstream consequence of the neurodegenerative disease process.
  - target: Developmental Regression
    description: Childhood-onset neurodegeneration leads to loss of previously acquired developmental function.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35628533
      reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
      explanation: Although the abstract does not use the term developmental regression directly, progressive childhood mental and motor deterioration partially supports loss of acquired skills.
  - target: Motor Deterioration
    description: >
      Progressive neurodegeneration produces loss of motor function across
      childhood-onset NCL presentations.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17564970
      reference_title: "The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "including age at onset from 2 to 7 years, epileptic seizures, psychomotor deterioration, myoclonus, loss of vision, and premature death."
      explanation: >
        Psychomotor deterioration in human late-infantile NCL supports motor
        deterioration downstream of progressive neurodegeneration.
  evidence:
  - reference: PMID:37022340
    reference_title: "Recent insights into the networking of CLN genes and proteins in mammalian cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In humans, mutations in CLN genes cause a devastating form of neurodegeneration called neuronal ceroid lipofuscinosis (NCL), commonly known as Batten disease."
    explanation: This review directly identifies NCL as a devastating form of neurodegeneration.
phenotypes:
- name: Visual Impairment
  category: Neurologic
  description: Progressive loss of vision is a common hallmark phenotype across NCL subtypes.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:35628533
    reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
    explanation: This review directly identifies progressive vision loss as a common NCL symptom.
- name: Retinal Degeneration
  category: Ophthalmologic
  description: >
    Progressive retinal degeneration is a tissue-level ocular phenotype that
    helps explain visual impairment in NCL.
  phenotype_term:
    preferred_term: Retinal degeneration
    term:
      id: HP:0000546
      label: Retinal degeneration
  evidence:
  - reference: PMID:25270050
    reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive retinal degeneration"
    explanation: >
      The human MFSD8 family report directly documents progressive retinal
      degeneration in affected NCL patients.
- name: Cognitive Impairment
  category: Neurologic
  description: NCL causes progressive decline in cognition and mental function.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:35628533
    reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
    explanation: The abstract identifies progressive mental deterioration as a common NCL manifestation, supporting progressive cognitive impairment.
- name: Seizures
  category: Neurologic
  description: Epileptic seizures are a frequent clinical manifestation of NCL.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:35628533
    reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
    explanation: This review directly lists epileptic seizures among the common symptoms of NCL.
- name: Developmental Regression
  category: Neurologic
  description: >
    Progressive deterioration of motor and cognitive function in childhood NCL
    commonly presents clinically as loss of previously acquired skills.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:35628533
    reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common symptoms of NCLs include the progressive loss of vision, mental and motor deterioration, epileptic seizures, premature death, and, in rare adult-onset cases, dementia."
    explanation: Although the review does not use the phrase developmental regression directly, progressive mental and motor deterioration in a childhood-onset neurodegenerative disorder partially supports loss of acquired developmental function.
- name: Motor Deterioration
  category: Neurologic
  description: >
    NCL causes progressive loss of motor abilities as part of the psychomotor
    deterioration seen in childhood-onset disease.
  phenotype_term:
    preferred_term: Motor deterioration
    term:
      id: HP:0002333
      label: Motor deterioration
  evidence:
  - reference: PMID:17564970
    reference_title: "The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including age at onset from 2 to 7 years, epileptic seizures, psychomotor deterioration, myoclonus, loss of vision, and premature death."
    explanation: >
      Human late-infantile NCL cases list psychomotor deterioration, supporting
      progressive motor deterioration.
- name: Myoclonus
  category: Neurologic
  description: >
    Myoclonus is a motor manifestation reported in late-infantile NCL
    presentations.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:17564970
    reference_title: "The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including age at onset from 2 to 7 years, epileptic seizures, psychomotor deterioration, myoclonus, loss of vision, and premature death."
    explanation: >
      Human late-infantile NCL cases explicitly include myoclonus.
biochemical:
- name: Autofluorescent ceroid lipopigment storage
  presence: INCREASED
  context: >
    NCL is defined pathologically by abnormal autofluorescent lysosomal storage
    material. No specific local CHEBI or NCIT term was found for ceroid
    lipofuscin, so this readout is represented without a forced biomarker term.
  readouts:
  - target: Autofluorescent Lipopigment Accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Increased autofluorescent storage material reports the core lysosomal
      lipopigment accumulation node.
    evidence:
    - reference: PMID:25270050
      reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
      explanation: >
        Human NCL evidence defines the storage lesion as lysosomal accumulation
        of abnormal autofluorescent material.
  evidence:
  - reference: PMID:25270050
    reference_title: "Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuronal ceroid lipofuscinosis (NCL) refers to a growing heterogeneous group of neurodegenerative disorders characterized by lysosomal accumulation of abnormal autofluorescent material."
    explanation: >
      Supports autofluorescent lysosomal storage material as the diagnostic
      biochemical/pathologic readout for the NCL group.
genetic:
- name: CLN Genes
  association: Pathogenic Mutations
  presence: Positive
  notes: >
    NCL is genetically heterogeneous, with multiple CLN genes encoding lysosomal
    enzymes, lysosomal transmembrane proteins, and related endomembrane-system
    proteins. This record is deliberately unbound: it names the locus family,
    not a gene, so there is no HGNC identifier for it. The individual genes are
    each curated as their own record below and are bound there.

    Some CLN numbers in the series are deliberately not curated on this umbrella.
    CLN4 (DNAJC5) and CLN13 (CTSF) are curated in
    Adult_Neuronal_Ceroid_Lipofuscinosis, which binds both genes and also binds
    CLN6. MONDO:0008768 ceroid lipofuscinosis, neuronal, 6B (Kufs type) therefore
    belongs to that entry rather than to this one; MONDO's own annotation on the
    6A term states that biallelic CLN6 variants can also cause juvenile or
    adult-onset disease known as Kufs disease, and it is the 6A form that is the
    has_subtypes row here.

    CLN14 (KCTD7) is the contested case and is not curated here. The 2015 genetics
    review cited on this record does list CLN14 among the NCL genes, as one of two
    cytoplasmic proteins that peripherally associate with membranes. Against that,
    ClinGen's Epilepsy Gene Curation Expert Panel - the same panel that curated
    the nine genes below against neuronal ceroid lipofuscinosis (MONDO:0016295) -
    curated KCTD7 against progressive myoclonus epilepsy (MONDO:0020074) instead,
    Definitive and autosomal recessive, in assertion
    CGGV:assertion_e6068b08-413e-4105-b8dc-97426d64c6c4-2022-09-07T160000.000Z.
    MONDO reflects the same split: MONDO:0012721 progressive myoclonic epilepsy type 3 is
    defined as "Any progressive myoclonic epilepsy in which the cause of the
    disease is a mutation in the KCTD7 gene", and carries both MONDO:0020074 and
    MONDO:0016295 as parents, the latter sourced from OMIM:611726 and
    Orphanet:263516. The KCTD7 disease therefore belongs in its own entry under
    progressive myoclonus epilepsy rather than as a subtype row here, and no
    such entry exists in this knowledge base yet.
  evidence:
  - reference: PMID:35628533
    reference_title: "Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, 13 autosomal recessive gene variants, as well as one autosomal dominant gene variant, of NCL have been described."
    explanation: This review summarizes the marked genetic heterogeneity of NCL across multiple causative CLN loci.
- name: CLN3
  gene_term:
    preferred_term: CLN3
    term:
      id: hgnc:2074
      label: CLN3
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN3 Disease
  evidence:
  - reference: CGGV:assertion_6be652b4-092f-4d1c-9606-4dfeb689c4b9-2023-04-04T040000.000Z
    reference_title: "CLN3 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLN3 | HGNC:2074 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the CLN3-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
- name: CLN5
  gene_term:
    preferred_term: CLN5
    term:
      id: hgnc:2076
      label: CLN5
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN5 Disease
  evidence:
  - reference: CGGV:assertion_a522b1d6-5ade-4749-94b8-d5426bbe5961-2021-09-08T023930.981Z
    reference_title: "CLN5 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLN5 | HGNC:2076 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the CLN5-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
- name: CLN6
  gene_term:
    preferred_term: CLN6
    term:
      id: hgnc:2077
      label: CLN6
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN6 Disease
  evidence:
  - reference: CGGV:assertion_09654b45-6649-4d11-b43e-aeb6d20fb86d-2020-12-01T170000.000Z
    reference_title: "CLN6 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLN6 | HGNC:2077 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the CLN6-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
- name: CLN8
  gene_term:
    preferred_term: CLN8
    term:
      id: hgnc:2079
      label: CLN8
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN8 Disease
  evidence:
  - reference: CGGV:assertion_68775ed0-576e-4ee7-90f2-d16329ecd7c1-2020-09-07T220116.243Z
    reference_title: "CLN8 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CLN8 | HGNC:2079 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the CLN8-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
- name: CTSD
  gene_term:
    preferred_term: CTSD
    term:
      id: hgnc:2529
      label: CTSD
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN10 Disease
  evidence:
  - reference: CGGV:assertion_d74b1b2a-52a3-4192-b5b4-e4fd46ffc0ba-2020-11-03T180000.000Z
    reference_title: "CTSD / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CTSD | HGNC:2529 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the CTSD-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
- name: GRN
  gene_term:
    preferred_term: GRN
    term:
      id: hgnc:4601
      label: GRN
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN11 Disease
  evidence:
  - reference: CGGV:assertion_49eb0915-acff-423d-a70f-d00d4319d404-2023-01-03T170000.000Z
    reference_title: "GRN / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GRN | HGNC:4601 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the GRN-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
- name: MFSD8
  gene_term:
    preferred_term: MFSD8
    term:
      id: hgnc:28486
      label: MFSD8
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN7 Disease
  evidence:
  - reference: CGGV:assertion_0f42cb66-5f28-4674-8f5a-76e15880bbfc-2020-12-15T170000.000Z
    reference_title: "MFSD8 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MFSD8 | HGNC:28486 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the MFSD8-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
- name: PPT1
  gene_term:
    preferred_term: PPT1
    term:
      id: hgnc:9325
      label: PPT1
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN1 Disease
  evidence:
  - reference: CGGV:assertion_ae7ebc05-9401-4932-afe2-a80e0d31e12f-2024-06-10T190000.000Z
    reference_title: "PPT1 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PPT1 | HGNC:9325 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the PPT1-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
- name: TPP1
  gene_term:
    preferred_term: TPP1
    term:
      id: hgnc:2073
      label: TPP1
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  inheritance:
  - name: Autosomal recessive
  subtype: CLN2 Disease
  evidence:
  - reference: CGGV:assertion_9b2f3b20-fb9a-4b5e-ad8e-e03be5ebb8e5-2020-09-26T005342.102Z
    reference_title: "TPP1 / neuronal ceroid lipofuscinosis (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TPP1 | HGNC:2073 | neuronal ceroid lipofuscinosis | MONDO:0016295 | AR | Definitive"
    explanation: ClinGen classifies the TPP1-neuronal ceroid lipofuscinosis gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Cerliponase Alfa
  description: >
    Enzyme replacement therapy used in CLN2 disease that slows decline in motor
    and language function.
  treatment_term:
    preferred_term: enzyme replacement therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
  target_mechanisms:
  - target: Progressive Neurodegeneration
    treatment_effect: INHIBITS
    description: >
      In CLN2 disease, intracerebroventricular cerliponase alfa slows motor and
      language decline, so it is modeled as inhibiting downstream progressive
      neurodegeneration in that subtype rather than as a cure for all NCL forms.
    evidence:
    - reference: PMID:31884868
      reference_title: "Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Treatment with intracerebroventricular cerliponase alfa resulted in slower decline of motor and language functions compared with natural history controls."
      explanation: >
        Clinical evidence in CLN2 supports cerliponase alfa as a disease-targeted
        therapy that slows functional decline.
  evidence:
  - reference: PMID:31884868
    reference_title: "Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment with intracerebroventricular cerliponase alfa resulted in slower decline of motor and language functions compared with natural history controls."
    explanation: This review summarizes clinical evidence that cerliponase alfa slows functional decline in CLN2 disease.
  - reference: PMID:31884868
    reference_title: "Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerliponase alfa is the first therapy for neuronal ceroid lipofuscinosis type 2 that targets the disease etiology."
    explanation: This identifies cerliponase alfa as an etiologically targeted treatment for the CLN2 subtype of NCL.
- name: Supportive Care
  description: >
    Palliative and symptomatic management remains the main treatment approach
    for most NCL subtypes.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lastly, we show the importance of palliative care and symptomatic treatments which are still the main therapeutic interventions."
    explanation: This review makes clear that supportive and symptomatic care remains the main intervention for most NCL forms.
datasets:
- accession: geo:GSE137420
  title: Synapse alterations precede neuronal damage and storage pathology in a human cerebral organoid  model of CLN3-Juvenile Neuronal Ceroid Lipofuscinosis
  description: We developed an invitro model for Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) using isogenic CLN3 mutated human iPS cell lines and performed transcriptomic profiling of brain organoids derived from these lines to identify transcriptomic changes in the early developing brain model.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 12
  publication: PMID:31888773
  notes: Identified by GEO DataSets index search for Neuronal Ceroid Lipofuscinosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE173665
  title: Brain transcriptome analysis of a TPP-1 neuronal ceroid lipofuscinosis mouse model as disease progresses
  description: We analyzed expression changes in the Tpp1-/- forebrain/midbrain and cerebellum of 1, 2, and 3 mo. mutants compared to strain-related controls RNA-sequencing technology.
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: BULK_RNA_SEQ
  sample_count: 36
  publication: PMID:34749772
  notes: Identified by GEO DataSets index search for Neuronal Ceroid Lipofuscinosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE297954
  title: Recreating pathophysiology of CLN2 disease and demonstrating reversion by TPP1 gene therapy in hiPSCs-derived retinal organoid and retina-on-chip
  description: Mutations in tripeptidyl peptidase 1 (TPP1) gene lead to late infantile neuronal ceroid lipofuscinosis CLN2, characterized by lysosomal accumulation of lipofuscins predominantly found in brain and retina. The ocular phenotype is characterized by bilateral outer retinal degeneration that leads to complete vision loss. CLN2 animal models struggle in recapitulating the retinal phenotype observed in patients. Here, we leveraged human induced pluripotent stem cell (hiPSC)-derived retinal organoids (ROs), retinal pigmented epithelial (RPE) cells, and retina-on-chip (RoC) technologies to model CLN2 disease in vitro in patient-specific microphysiological models of the human retina.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 16
  publication: PMID:40706588
  notes: Identified by GEO DataSets index search for Neuronal Ceroid Lipofuscinosis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: massive:MSV000081143
  title: iTRAQ8 analysis of control and neuronal ceroid lipofuscinosis human brain samples.
  description: iTRAQ8 analysis of autopsy samples representing brain and cerebrospinal fluid from neuronal ceroid lipofuscinosis patients and controls.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Neuronal Ceroid Lipofuscinosis"). Retrieved 2026-08-02.
📚

References & Deep Research

References

1
PMID:20301601
Neuronal Ceroid Lipofuscinoses Overview.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Neuronal Ceroid Lipofuscinosis. Core disease mechanisms, molecular and cel...
Asta Scientific Corpus Retrieval 20 citations 2026-03-30T17:39:31.062954

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Neuronal Ceroid Lipofuscinosis. Core disease mechanisms, molecular and cel...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 20
  • Snippets retrieved: 20

Relevant Papers

[1] Recent insights into the networking of CLN genes and proteins in mammalian cells

  • Authors: R. Huber
  • Year: 2023
  • Venue: Journal of Neurochemistry
  • URL: https://www.semanticscholar.org/paper/cc429c474e95d5a631782adfbe20b36532519e9c
  • DOI: 10.1111/jnc.15822
  • PMID: 37022340
  • Citations: 11
  • Summary: A deeper understanding of the pathways and cellular processes impacted by mutations in CLN genes will not only strengthen the knowledge of the pathological mechanisms underlying the NCLs but may also provide new insight into related forms of neurodegeneration.
  • Evidence snippets:
  • Snippet 1 (score: 0.570) > Ceroid lipofuscinosis neuronal (CLN) genes encode 13 proteins that localize throughout the endomembrane system to regulate a variety of cellular processes. In humans, mutations in CLN genes cause a devastating form of neurodegeneration called neuronal ceroid lipofuscinosis (NCL), commonly known as Batten disease. Each CLN gene is associated with a specific subtype of the disease that differ from each other in severity and age of onset. The NCLs affect all ages and ethnicities worldwide but primarily affect children. The pathology underlying the NCLs is poorly understood, which has prevented the development of a cure or effective therapy for most subtypes of the disease. A growing body of literature supports the networking of CLN genes and proteins within cells, which aligns with the broadly similar cellular and clinical manifestations among the different subtypes of NCL. Here, all relevant literature is reviewed to provide a comprehensive overview of our current understanding of how CLN genes and proteins are networked in mammalian cells with an aim toward revealing new molecular targets for therapy development. Intriguingly, CLN gene and protein networking extends beyond the NCLs as recent work has linked several CLN genes and proteins to other forms of neurodegeneration such as Alzheimer's disease and Parkinson's disease. Thus, a deeper understanding of the pathways and cellular processes impacted by mutations in CLN genes will not only strengthen our knowledge of the pathological mechanisms underlying the NCLs but may also provide new insight into related forms of neurodegeneration.

[2] Neuronal Ceroid Lipofuscinoses: Connecting Calcium Signalling through Calmodulin

  • Authors: Sabateeshan Mathavarajah, D. O’Day, R. Huber
  • Year: 2018
  • Venue: Cells
  • URL: https://www.semanticscholar.org/paper/3d007c8ea7ed8f4da2c267fc85c5aa5f10a1c1d1
  • DOI: 10.3390/cells7110188
  • PMID: 30380624
  • PMCID: 6262527
  • Citations: 13
  • Summary: It is shown that 11 of the 13 NCL proteins contain putative CaM-binding domains (CaMBDs), which indicates that targeting CaM may be a valid therapeutic approach for treating the disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.540) > The first clinical diagnosis of Batten disease was in 1903, and since then, great strides have been made in our understanding of the cellular and molecular mechanisms underlying this devastating neurological disorder [1].Batten disease, which is clinically known as neuronal ceroid lipofuscinosis (NCL), is a form of neurodegeneration that has a global distribution and affects people of all ages [2].Clinical manifestations of the disease include vision loss, seizures, progressive loss of motor function and cognitive ability, and a reduced lifespan [3].The only clinically-approved therapeutic for the NCLs is Brineura, which is an enzyme replacement therapy specific for only one subtype of the disease (i.e., CLN2 disease) [4].The absence of therapeutics stems from our poor understanding of NCL proteins and their primary functions.In total, 13 genetically distinct genes are linked to the disease (CLN1-8, CLN10-14) [2].These 13 genes encode enzymes (CLN1, CLN2, CLN5, CLN10, and CLN13), transmembrane proteins (CLN3, CLN7, and CLN12), membrane proteins that localize to the endoplasmic reticulum (CLN6 and CLN8), cytoplasmic proteins (CLN11 and CLN14), and a protein found on synaptic vesicles (CLN4) [2].Along with distinct localizations, the NCL proteins have been linked to fundamental cellular processes, including sphingolipid metabolism, protein degradation, and lysosomal pH homeostasis, among others [5][6][7][8][9][10].Since mutations in NCL proteins cause nearly identical clinical phenotypes, they are thought to participate in shared or convergent biological pathways [11].However, the common link between the proteins has yet to be revealed. > For clues to explain the molecular networking of NCL proteins, research groups have looked for reoccurring phenotypes in NCL patients [12].

[3] An altered transcriptome underlies cln5-deficiency phenotypes in Dictyostelium discoideum

  • Authors: William D. Kim, R. Huber
  • Year: 2022
  • Venue: Frontiers in Genetics
  • URL: https://www.semanticscholar.org/paper/efb8f8960b6eb7c4d516f1194de8dbffd5d61fb0
  • DOI: 10.3389/fgene.2022.1045738
  • PMID: 36437924
  • PMCID: 9686302
  • Citations: 1
  • Summary: The impact of cln5-deficiency on gene expression in D. discoideum is revealed, insight is provided on the genes and proteins that play a role in regulating ClN5-dependent processes, and light is shed on the molecular mechanisms underlying CLN5 disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.539) > The neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, are a family of neurodegenerative diseases linked to mutations in 13 ceroid lipofuscinosis neuronal (CLN) genes (CLN1-8, CLN10-14) (Schulz et al., 2013;Mole and Cotman, 2015). Each of the 13 different subtypes of NCL are characterized by the lysosomal accumulation of autoflourescent lipid-protein aggregates called ceroid lipofuscin in neurons, as well as other cell types outside the central nervous system (Palmer et al., 1992;Mole and Cotman, 2015). The accumulation of ceroid lipofuscin has been associated with numerous clinical symptoms, including seizures, reduced motor, visual, and cognitive function, as well as a reduced lifespan (Schulz et al., 2013;Mole and Cotman, 2015). While most of the CLN genes have been studied, the precise cellular mechanisms impacted by CLN gene mutations remain elusive. > Mutations in CLN5 cause the CLN5 disease subtype of NCL (Schulz et a., 2013;Mole and Cotman, 2015). CLN5 is a soluble lysosomal and extracellular protein that is predicted to function as either a glycoside hydrolase or depalmitoylase (Isosomppi et al., 2002;Hughes et al., 2014;Jules et al., 2017;Huber and Mathavarajah, 2018a;Basak et al., 2021b;Luebben et al., 2022). CLN5 has been linked to several cellular processes including, but not limited to, endosomal sorting, biometal homeostasis, sphingolipid metabolism, and autophagy (El Haddad et al., 2012;Mamo et al., 2012;Grubman et al., 2014;Doccini et al., 2020;McLaren et al., 2021). However, like most CLN proteins, the association of CLN5 with a defined biological pathway is still under investigation.

[4] Induced Pluripotent Stem Cells Derived from a CLN5 Patient Manifest Phenotypic Characteristics of Neuronal Ceroid Lipofuscinoses

  • Authors: K. Uusi-Rauva, T. Blom, Carina von Schantz-Fant, Tomas Blom, A. Jalanko et al.
  • Year: 2017
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/be3792a8185e9d7a32a9b59780e8ec7c1f39220a
  • DOI: 10.3390/ijms18050955
  • PMID: 28468312
  • PMCID: 5454868
  • Citations: 33
  • Summary: Neuronal ceroid lipofuscinoses (NCLs) are autosomal recessive progressive encephalopathies caused by mutations in at least 14 different genes. Despite extensive studies performed in different NCL animal models, the molecular mechanisms underlying neurodegeneration in NCLs remain poorly understood. To model NCL in human cells, we generated induced pluripotent stem cells (iPSCs) by reprogramming skin fibroblasts from a patient with CLN5 (ceroid lipofuscinosis, neuronal, 5) disease, the late inf...
  • Evidence snippets:
  • Snippet 1 (score: 0.537) > Neuronal ceroid lipofuscinoses (NCLs) are autosomal recessive progressive encephalopathies caused by mutations in at least 14 different genes. Despite extensive studies performed in different NCL animal models, the molecular mechanisms underlying neurodegeneration in NCLs remain poorly understood. To model NCL in human cells, we generated induced pluripotent stem cells (iPSCs) by reprogramming skin fibroblasts from a patient with CLN5 (ceroid lipofuscinosis, neuronal, 5) disease, the late infantile variant form of NCL. These CLN5 patient-derived iPSCs (CLN5Y392X iPSCs) harbouring the most common CLN5 mutation, c.1175_1176delAT (p.Tyr392X), were further differentiated into neural lineage cells, the most affected cell type in NCLs. The CLN5Y392X iPSC-derived neural lineage cells showed accumulation of autofluorescent storage material and subunit C of the mitochondrial ATP synthase, both representing the hallmarks of many forms of NCLs, including CLN5 disease. In addition, we detected abnormalities in the intracellular organelles and aberrations in neuronal sphingolipid transportation, verifying the previous findings obtained from Cln5-deficient mouse macrophages. Therefore, patient-derived iPSCs provide a suitable model to study the mechanisms of NCL diseases.

[5] Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview

  • Authors: A. Simonati, Ruth E. Williams
  • Year: 2022
  • Venue: Frontiers in Neurology
  • URL: https://www.semanticscholar.org/paper/958b94cb5357170fef4d725e2b10655492abf845
  • DOI: 10.3389/fneur.2022.811686
  • PMID: 35359645
  • PMCID: 8961688
  • Citations: 59
  • Influential citations: 2
  • Summary: The main aim of this review is to summarize the current state-of-art in the field of childhood Neuronal Ceroid Lipofuscinosis, a group of rare neurodegenerative disorders, and describe the large variety of experimental models which have aided this research, as well as the most recent technological developments which have shed light on the main mechanisms involved in the cellular pathology.
  • Evidence snippets:
  • Snippet 1 (score: 0.525) > The main aim of this review is to summarize the current state-of-art in the field of childhood Neuronal Ceroid Lipofuscinosis (NCL), a group of rare neurodegenerative disorders. These are genetic diseases associated with the formation of toxic endo-lysosomal storage. Following a brief historical review of the evolution of NCL definition, a clinically-oriented approach is used describing how the early symptoms and signs affecting motor, visual, cognitive domains, and including seizures, may lead clinicians to a rapid molecular diagnosis, avoiding the long diagnostic odyssey commonly observed. We go on to focus on recent advances in NCL research and summarize contributions to knowledge of the pathogenic mechanisms underlying NCL. We describe the large variety of experimental models which have aided this research, as well as the most recent technological developments which have shed light on the main mechanisms involved in the cellular pathology, such as apoptosis and autophagy. The search for innovative therapies is described. Translation of experimental data into therapeutic approaches is being established for several of the NCLs, and one drug is now commercially available. Lastly, we show the importance of palliative care and symptomatic treatments which are still the main therapeutic interventions.

[6] Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease

  • Authors: E. Shematorova, G. V. Shpakovski
  • Year: 2020
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/140bc3d40a51eb872ceb3c3d39dcc450eff8c479
  • DOI: 10.3390/ijms21218055
  • PMID: 33137890
  • PMCID: 7663513
  • Citations: 4
  • Summary: The main recorded to date changes in cell metabolism, to some extent contributing to the emergence and progression of JNCL disease, and human-specific molecular features of CLN3 gene expression are summarized and critically discussed with an emphasis on the possible molecular mechanisms of the malady appearance and progression.
  • Evidence snippets:
  • Snippet 1 (score: 0.524) > The neuronal ceroid lipofuscinoses (NCLs) collectively constitute one of the most common forms of inherited childhood-onset neurodegenerative disorders. They form a heterogeneous group of incurable lysosomal storage diseases that lead to blindness, motor deterioration, epilepsy, and dementia. Traditionally the NCL diseases were classified according to the age of disease onset (infantile, late-infantile, juvenile, and adult forms), with at least 13 different NCL varieties having been described at present. The current review focuses on classic juvenile NCL (JNCL) or the so-called Batten (Batten-Spielmeyer-Vogt; Spielmeyer-Sjogren) disease, which represents the most common and the most studied form of NCL, and is caused by mutations in the CLN3 gene located on human chromosome 16. Most JNCL patients carry the same 1.02-kb deletion in this gene, encoding an unusual transmembrane protein, CLN3, or battenin. Accordingly, the names CLN3-related neuronal ceroid lipofuscinosis or CLN3-disease sometimes have been used for this malady. Despite excessive in vitro and in vivo studies, the precise functions of the CLN3 protein and the JNCL disease mechanisms remain elusive and are the main subject of this review. Although the CLN3 gene is highly conserved in evolution of all mammalian species, detailed analysis of recent genomic and transcriptomic data indicates the presence of human-specific features of its expression, which are also under discussion. The main recorded to date changes in cell metabolism, to some extent contributing to the emergence and progression of JNCL disease, and human-specific molecular features of CLN3 gene expression are summarized and critically discussed with an emphasis on the possible molecular mechanisms of the malady appearance and progression.

[7] Benchmarking Nanopore Sequencing for CLN2 (TPP1) Mutation Detection: Integrating Rapid Genomics and Orthogonal Validation for Precision Diagnostics

  • Authors: Betül Teker, Gokce Akan, H. Kazan, Özge Özgen, S. Tatonyan et al.
  • Year: 2025
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/17ab4c1d747ef2acbf7649f4009dc7c8e878e55f
  • DOI: 10.3390/ijms26115037
  • PMID: 40507848
  • PMCID: 12155472
  • Summary: This study aimed to benchmark the performance of Oxford Nanopore long-read sequencing (ONT-LRS) for targeted TPP1 mutation detection in a Turkish CLN2 cohort and to assess its concordance with orthogonal validation methods, including Sanger sequencing and enzymatic activity assays.
  • Evidence snippets:
  • Snippet 1 (score: 0.521) > Neuronal ceroid lipofuscinosis type 2 (CLN2) disease (OMIM 204500), also known as Jansky-Bielschowsky, represents an exceptionally rare lysosomal storage disorder within the neuronal ceroid lipofuscinosis (NCL) family, collectively termed Batten disease. Previously known as late-infantile neuronal ceroid lipofuscinosis (LINCL), CLN2 disease is an early childhood onset disorder caused by autosomal recessive mutations in the TPP1 gene (GenBank accession no. NM_000391.3) localized on chromosome 11p15. These mutations result in deficient activity of the lysosomal exopeptidase tripeptidyl peptidase 1 (TPP1) (EC 3.4.14.9) [1]. Similar to other NCL disorders (CLN1-CLN14), CLN2 disease involves lysosomal dysfunction, which culminates in the accumulation of autofluorescent storage materials, subsequent neuronal loss, and neurodegeneration. However, the precise in vivo substrates and the complete pathologic mechanisms remain incompletely characterized [2]. > Pathogenic TPP1 gene variants, including splice site, missense, and nonsense mutations, as well as small deletions or insertions, primarily result in diminished or absent enzyme activity, impaired neuropeptide degradation, and the accumulation of subunit c of ATP synthase. This results in the lysosomal accumulation of ceroid lipofuscin, glial activation, and neuronal loss [3]. These mutations lead to reduced or absent TPP1 activity, resulting in lysosomal accumulation of ceroid lipofuscin, a hallmark of the CLN2 phenotype [4][5][6]. Ultrastructural analysis of lysosomal storage in CLN2 disease reveals a characteristic curvilinear profile [6,7]. Clinically, symptom onset correlates with peak TPP1 expression (ages 2-4) and includes new-onset seizures, ataxia, and a history of language delay [8].

[8] Behavioural and Medical Differentials of Cognitive Decline and Dementia in Dogs and Cats

  • Authors: S. Denenberg, F. Liebel, J. Rose
  • Year: 2017
  • Venue: Canine and Feline Dementia
  • URL: https://www.semanticscholar.org/paper/c55376bb9d5213c0a38e6aa0bffd5f54e6bd5df6
  • DOI: 10.1007/978-3-319-53219-6_2
  • PMCID: 7121040
  • Citations: 9
  • Summary: Cognitive dysfunction syndrome (CDS) is a diagnosis of exclusion given that there is no specific diagnostic test or tool and that medical disorders can cause the same set of signs.
  • Evidence snippets:
  • Snippet 1 (score: 0.520) > Aetiopathogenesis Ceroid lipofuscinosis is a neurodegenerative disease characterised by the accumulation of autofluorescent lipopigments (ceroid-or lipofuscin-like lipopigments) in neurons and other cells within the body. While most affected dogs and cats will present with signs early in life (within the first 2 years), ceroid lipofuscinosis is one of the few storage diseases that can present in adulthood. This is particularly true in the Tibetan terrier and dachshund breeds who may develop obvious signs when 6 years or older and can survive past 10 years of age. The pathophysiology of the disease is yet to be elucidated as it is unclear whether the mechanism of injury is a direct consequence of the pigment accumulation in cells or if it involves an abnormal mitochondrial function. The advances of molecular genetics have permitted the identification of multiple gene defects causing enzymatic dysfunction, leading to ceroid lipofuscinosis in specific dog breeds.

[9] Editorial: Neuronal ceroid lipofuscinosis: A multidisciplinary update

  • Authors: Alessandro Simonati, R. E. Williams, Angela Schulz
  • Year: 2022
  • Venue: Frontiers in Neurology
  • URL: https://www.semanticscholar.org/paper/c6c2f43109e69130ad717ac0c0cac6dac945c199
  • DOI: 10.3389/fneur.2022.1083113
  • PMID: 36468054
  • PMCID: 9710275
  • Summary: a
  • Evidence snippets:
  • Snippet 1 (score: 0.520) > Eleven papers and fifty-one authors from seven countries have contributed to the Research Topic Neuronal Ceroid Lipofuscinosis: a Multidisciplinary Update. Both clinical and research issues have been addressed in this collection of articles. The first paper provides a broad introduction and subsequent articles cover epidemiology and genetics, diagnosis, natural history studies, treatment and ethical implications of novel therapies, cardiac involvement in the later stages of disease and the underlying pathological mechanisms. > The state-of-art in the field of childhood NCLs was described from a number of perspectives in the first review paper of the series (Simonati and Williams). Following a brief historical survey, a clinically-oriented approach was used to describe how the early symptoms and signs represent topographical signatures of the underlying brain dysfunction and may provide clues helping clinicians to reach a conclusive NCL diagnosis rapidly. The paper goes on to document advances in NCL research and the contributions of different experimental models to enhance knowledge of the pathogenic mechanisms underlying cellular pathology in this group of diseases. Lastly, translation of experimental data into novel therapeutic approaches and the importance of symptomatic treatments, which remain the main available therapeutic approaches, were outlined. > The world-wide distribution of NCL was emphasized by the retrospective epidemiological study from South America and the Caribbean region, in which CLN2, CLN6, and CLN3 disorders were identified as the most common NCL types in those regions (Guelbert et al.). The authors have stressed that synergy between health providers, parent support organizations and the pharmaceutical industry have accelerated the use of modern diagnostic procedures. > The significance of the advances in genetic studies in NCL was discussed in the review article by Gardner and Mole which focuses on the genetic basis of phenotypic heterogeneity (Gardner and Mole). Since the discovery of the first causative genes, more than 530 mutations have been identified across 13 NCL genes. Increasing numbers of variant disease phenotypes are being described. Identification of phenotypic heterogeneity combined with the genetic background of each patient is necessary in order to facilitate individually tailored precision medicine in order to modify disease progression in the approaching genomic medicine era.

[10] Gene therapy ameliorates spontaneous seizures associated with cortical neuron loss in a Cln2R207X mouse model

  • Authors: Keigo Takahashi, Elizabeth M. Eultgen, Sophie H. Wang, N. Rensing, H. Nelvagal et al.
  • Year: 2023
  • Venue: The Journal of Clinical Investigation
  • URL: https://www.semanticscholar.org/paper/d4b32684c244c570a7ff5c79b249440a291ee06b
  • DOI: 10.1172/JCI165908
  • PMID: 37104037
  • PMCID: 10266778
  • Citations: 13
  • Summary: Investigation of the nature and progression of neurological and underlying neuropathological changes in Cln2R207X mice revealed progressive epileptiform abnormalities, including spontaneous seizures, providing a robust, quantifiable, and clinically relevant phenotype, and highlights the importance of clinically relevant outcome measures for judging preclinical efficacy of therapeutic interventions for CLN2 disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.508) > Although a disease-modifying therapy for classic late infantile neuronal ceroid lipofuscinosis (CLN2 disease) exists, poor understanding of cellular pathophysiology has hampered the development of more effective and persistent therapies. Here, we investigated the nature and progression of neurological and underlying neuropathological changes in Cln2R207X mice, which carry one of the most common pathogenic mutations in human patients but are yet to be fully characterized. Long-term electroencephalography recordings revealed progressive epileptiform abnormalities, including spontaneous seizures, providing a robust, quantifiable, and clinically relevant phenotype. These seizures were accompanied by the loss of multiple cortical neuron populations, including those stained for interneuron markers. Further histological analysis revealed early localized microglial activation months before neuron loss started in the thalamocortical system and spinal cord, which was accompanied by astrogliosis. This pathology was more pronounced and occurred in the cortex before the thalamus or spinal cord and differed markedly from the staging seen in mouse models of other forms of neuronal ceroid lipofuscinosis. Neonatal administration of adeno-associated virus serotype 9–mediated gene therapy ameliorated the seizure and gait phenotypes and prolonged the life span of Cln2R207X mice, attenuating most pathological changes. Our findings highlight the importance of clinically relevant outcome measures for judging preclinical efficacy of therapeutic interventions for CLN2 disease.

[11] The converging roles of Batten disease proteins in neurodegeneration and cancer

  • Authors: S. Q. Yap, Sabateeshan Mathavarajah, R. Huber
  • Year: 2021
  • Venue: iScience
  • URL: https://www.semanticscholar.org/paper/d5a9630c4e492fd532c0ccc5c7543b976dd78e6a
  • DOI: 10.1016/j.isci.2021.102337
  • PMID: 33889828
  • PMCID: 8050770
  • Citations: 16
  • Influential citations: 1
  • Summary: It is proposed that further research on the relationship between cancer and the NCLs may help shed light on the roles of NCL genes in both diseases and possibly guide therapy development.
  • Evidence snippets:
  • Snippet 1 (score: 0.507) > patient-database). Each gene is associated with a different subtype of NCL (Mole and Cotman, 2015). A recent study showed that mutations in the TBCK (TBC1 domain-containing kinase) gene present characteristics and clinical pathology that resemble other NCL subtypes, and thus, may be classified as a new NCL subtype, CLN15 disease (Beck- Wo ¨dl et al., 2018). The NCL family of proteins comprises soluble lysosomal enzymes (CLN1/PPT1, palmitoyl protein thioesterase 1; CLN2/TPP1, tripeptidyl peptidase 1; CLN5, ceroid lipofuscinosis neuronal 5; CLN10/CTSD, cathepsin D; CLN13/CTSF, cathepsin F), lysosomal transmembrane proteins (CLN3, ceroid lipofuscinosis neuronal 3; CLN7/MFSD8, major facilitator superfamily domain-containing 8; CLN12/ATP13A2, ATPase 13A2), proteins associated with vesicular membranes (CLN4/DNAJC5, DnaJ heat shock protein family member C5; CLN14/KCTD7, potassium channel tetramerization domain-containing 7), membrane proteins that reside in the endoplasmic reticulum (ER) (CLN6, ceroid lipofuscinosis neuronal 6; CLN8, ceroid lipofuscinosis neuronal 8) and a secreted glycoprotein (CLN11/ PGRN, progranulin) (Ca ´rcel-Trullols et al., 2015). Despite the molecular genetic heterogeneity of these proteins, research in non-mammalian and mammalian models suggests that the NCL proteins may participate in shared or converging pathways (Huber, 2020;Persaud-Sawin et al., 2007). However, the precise functions of NCL proteins, their interactions with one another, and the underlying mechanisms that lead to NCL pathology are poorly understood, which has severely hindered therapy development.

[12] CLN8 Gene Compound Heterozygous Variants: A New Case and Protein Bioinformatics Analyses

  • Authors: R. Sharkia, Abdelnaser Zalan, Hazar Zahalka, Amit Kessel, Ayman Asaly et al.
  • Year: 2022
  • Venue: Genes
  • URL: https://www.semanticscholar.org/paper/10d2f0913f50a81aa537459dbb641e38b708009c
  • DOI: 10.3390/genes13081393
  • PMID: 36011304
  • PMCID: 9407845
  • Citations: 5
  • Summary: Two patients who presented with atypical phenotypic manifestation and protracted clinical course of CLN8 carrying a novel compound heterozygous variant at theCLN8 gene are described, which confirmed and expanded the effect of compoundheterozygous variants in CLn8 disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.506) > Neuronal ceroid lipofuscinosis (NCL) refers to a group of rare disorders that affects human neurons which is one of the most common causes of progressive neurological deterioration in childhood. It involves the buildup of an abnormal material called lipofuscin in the brain. NCL is inherited from the parents by their progeny in an autosomal recessive manner. There are three main types of NCL namely, Adult (Kufs or Parry disease), Juvenile (Batten disease), and Late infantile (Jansky-Bielschowsky disease) [1]. The late infantile type is the most heterogeneous one, with several variants and four genes identified: CLN2, CLN5, CLN6, and CLN8 [2]. > The accumulation of autofluorescent lysosomal storage material in the central nervous system is a key pathological finding of NCL. Several possible candidate genes (13 genes) are involved in this process, namely, CLN1 to CLN8, and CLN10 to CLN14 [3]. To date, more than 430 pathogenic variants in the above 13 candidate genes have been reported in human NCLs, and most have been registered in the NCL Mutation Database [4][5][6]. As a collective group, NCL patients are typically defined by observation of cognitive and visual impairments, epileptic seizures, and deterioration of motor skills and balance issues [7]. Unfortunately, there is no cure for NCL disorders. Therapeutic approaches for the treatment of many NCLs include the administration of immunosuppressive agents to antagonize neuroinflammation associated with neurodegeneration, the use of various small molecules, stem cell therapy, and gene therapy [8]. > The CLN8 disease type is clinically recognized during childhood in which two main clinical phenotypes were described, namely "Northern Epilepsy" known as the Finnish type characterized by intractable epilepsy and cognitive regression at the ages 5-10 years [9]. The second phenotype was the late-infantile NCL characterized by earlier onset and more rapid progressive course with visual failure, ataxia, mental decline, and epilepsy [10,11].

[13] Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis

  • Authors: Konrad Kaminiów, S. Kozak, J. Paprocka
  • Year: 2022
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/afdbc0b7fdf7649d5c1ae6309a182f7c4c222633
  • DOI: 10.3390/ijms23105729
  • PMID: 35628533
  • PMCID: 9145894
  • Citations: 30
  • Influential citations: 2
  • Summary: An overview of the current knowledge regarding the pathophysiology, genetics, and clinical manifestation of these conditions, as well as the approach to diagnosis is provided.
  • Evidence snippets:
  • Snippet 1 (score: 0.499) > The situation is different, for example, in infantile neuronal ceroid lipofuscinosis type 1 (CLN1), where seizure frequency tends to decrease in the later stages of the disease, or in patients with classic juvenile CLN3, where seizures are rare and only moderate severity occurs in the later stages of the disease [3,[141][142][143]. As the disease progresses, the benefits and harms of specific medications should be reconsidered, as these drugs, while tolerable and effective in the earlier stages of the disease, may prove ineffective after progression and cause only side effects [143]. > Typical neurological manifestations of NCL also include motor symptoms, such as ataxia, dysphagia, myoclonus, chorea, tremors, and dystonia [3]. These especially occur in the classic and late infantile phenotypes [3,13]. In addition, parkinsonism is also present, especially in juvenile CLN3 disease, and some stereotypic movements have also been described in various types of NCL with late infantile and juvenile onset [3,13]. Table 3 shows the clinical characteristics of the different subtypes of neuronal ceroid lipofuscinoses.

[14] Epilepsy in neurodegenerative diseases.

  • Authors: S. Neri, G. Mastroianni, E. Gardella, U. Aguglia, G. Rubboli
  • Year: 2022
  • Venue: Epileptic disorders : international epilepsy journal with videotape
  • URL: https://www.semanticscholar.org/paper/3a35529b660901b3c98f454b81976b96a350406c
  • DOI: 10.1684/epd.2021.1406
  • PMID: 35596580
  • Citations: 56
  • Influential citations: 1
  • Summary: An updated overview of the clinical features, pathophysiological mechanisms and diagnostic and treatment approaches of epilepsy in the most common neurodegenerative disorders (such as Alzheimer disease and other types of dementia, Parkinson disease, Down syndrome, prion diseases, and progressive myoclonus epilepsies) is provided to provide a tool that can help epileptologists and neurologists in the diagnosis and management of this increasingly reported comorbidity.
  • Evidence snippets:
  • Snippet 1 (score: 0.498) > Neuronal ceroid lipofuscinosis (NCL), also known as Batten disease, comprises a group of neurodegenerative lysosomal storage disorders resulting in excessive accumulation of lipopigments [96]. NCLs are characterized by progressive decline of cognitive and motor functions, retinopathy with evolution to blindness, varying degrees of brain atrophy, and myoclonic epilepsy [95]. There are 14 forms of neuronal ceroid lipofuscinosis, classified according to age of symptom onset (varying from infancy and childhood to adulthood) and causative gene mutation [96]. ASMs commonly used are lamotrigine and valproic acid. Topiramate and levetiracetam can be also effective while carbamazepine, phenytoin and gabapentin may worsen myoclonic seizures [95]. Infantile NCL is a severe disease of infancy, which presents with seizures, developmental arrest and regression, and visual loss. The main gene involved in this form is CLN1, which encodes a lysosomal palmitoyl protein thioesterase. More severe than CLN1 is CLN10, which is a congenital fatal condition characterized by encephalopathy with respiratory insufficiency and status epilepticus. CLN10 encodes the lysosomal protease, cathepsin D [96]. Late-infantile NCL presents with onset in early childhood and is caused by pathogenic variants of the CLN2 gene. This disorder is characterized at the onset by a very severe myoclonic epilepsy, followed during the course of the disease, by cognitive and motor decline, and later by visual loss. CLN2 encodes a lysosomal tripeptidyl peptidase. Other NCLs such as CLN5, CLN6, CLN7, CLN8, and CLN14 mimic, to various extents, the clinical phenotype of the classic CLN2. Mild CLN6 mutations are another cause of adolescence or adult-onset PME [96]. CLN6 encodes an endoplasmic reticulum protein of unclear function.

[15] MRI findings of neuronal ceroid lipofuscinosis in a cat

  • Authors: Crystal White, J. Mortier, R. Verin, T. Maddox, R. Gonçalves et al.
  • Year: 2018
  • Venue: JFMS Open Reports
  • URL: https://www.semanticscholar.org/paper/0a2ded6cbd632857d491140a57f2773c3610b10b
  • DOI: 10.1177/2055116918757330
  • PMID: 29531776
  • PMCID: 5843104
  • Citations: 6
  • Influential citations: 1
  • Summary: MRI examination revealed generalised cerebral and cerebellar atrophy, diffuse T2-weighted hyperintensity of the white matter and meningeal thickening, the first report of the MRI findings of neuronal ceroid lipofuscinosis in a cat.
  • Evidence snippets:
  • Snippet 1 (score: 0.492) > Traditionally and still commonly encountered in the literature, nomenclature was based on the age of clinical presentation, for example infantile/juvenile/adult. The storage material, along with its ultrastructure, is variable for each neuronal ceroid lipofuscinosis type, and, although similar, the clinical course is slightly altered for each one. Molecular analysis has identified the genetic loci for the neuronal ceroid lipofuscinosis types in humans, with the exception of the CLN9 gene, which remains elusive. 23 The differences in the mutations account for the variable phenotypes between the types. 24 ][27][28] Sequencing of the exons of CLN1, CLN3, CLN5, CLN8 and CLN10 in a confirmed case of feline neuronal ceroid lipofuscinosis failed to identify the molecular cause in that patient. 4 The genes involved in the development of feline neuronal ceroid lipofuscinosis remain unidentified. > In humans and dogs, neuronal ceroid lipofuscinosis has been shown to be a recessively inherited disease with the progeny of two carrier parents having a one in four chance of developing the disease. 14 A second cat, from the same litter as the cat in this case, developed similar clinical signs 4 weeks after its littermate and was euthansed owing to severity of clinical signs. Histopathology and TEM confirmed neuronal ceroid lipofuscinosis in this second cat with central nervous system morphological changes similar to the cat described in this case. MRI was not performed in this second case, but pathological findings and the relationship between the two littermates reinforce the hypothesis of an inherited mutation in cats. 3

[16] Revoking the Seize Order: Preventing Spontaneous Seizures With AAV in a CLN2 Mouse Model

  • Authors: Gordon F. Buchanan
  • Year: 2023
  • Venue: Epilepsy Currents
  • URL: https://www.semanticscholar.org/paper/385f73ebc8d00dc9e7c2f433dd8be7625868cc8f
  • DOI: 10.1177/15357597231200702
  • PMID: 38269343
  • PMCID: 10805085
  • Summary: Investigation of the nature and progression of neurological and underlying neuropathological changes in Cln2R207X mice revealed progressive epileptiform abnormalities, including spontaneous seizures, providing a robust, quantifiable, and clinically relevant phenotype, and highlights the importance of clinically relevant outcome measures for judging preclinical efficacy of therapeutic interventions for CLN2 disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.491) > Although a disease-modifying therapy for classic late infantile neuronal ceroid lipofuscinosis (CLN2 disease) exists, poor understanding of cellular pathophysiology has hampered the development of more effective and persistent therapies. Here, we investigated the nature and progression of neurological and underlying neuropathological changes in Cln2 R207X mice, which carry one of the most common pathogenic mutations in human patients but are yet to be fully characterized. Long-term electroencephalography recordings revealed progressive epileptiform abnormalities, including spontaneous seizures, providing a robust, quantifiable, and clinically relevant phenotype. These seizures were accompanied by the loss of multiple cortical neuron populations, including those stained for interneuron markers. Further histological analysis revealed early localized microglial activation months before neuron loss started in the thalamocortical system and spinal cord, which was accompanied by astrogliosis. This pathology was more pronounced and occurred in the cortex before the thalamus or spinal cord and differed markedly from the staging seen in mouse models of other forms of neuronal ceroid lipofuscinosis. Neonatal administration of adeno-associated virus serotype 9-mediated gene therapy ameliorated the seizure and gait phenotypes and prolonged the life span of Cln2 R207X mice, attenuating most pathological changes. Our findings highlight the importance of clinically relevant outcome measures for judging preclinical efficacy of therapeutic interventions for CLN2 disease.

[17] Visual perception and macular integrity in non-classical CLN2 disease

  • Authors: Y. Atiskova, Jan Wildner, E. Wibbeler, M. Nickel, M. Spitzer et al.
  • Year: 2022
  • Venue: Graefe's Archive for Clinical and Experimental Ophthalmology
  • URL: https://www.semanticscholar.org/paper/af4a1c78a0616dad65d14e16df890f0a22666833
  • DOI: 10.1007/s00417-022-05662-1
  • PMID: 35652945
  • PMCID: 9581810
  • Citations: 1
  • Summary: The presented longitudinal study characterizes the variable ocular involvement in non-classical CLN2 disease and contributes to the natural history description, outlining the necessity of regular ophthalmic examination.
  • Evidence snippets:
  • Snippet 1 (score: 0.488) > Neuronal ceroid lipofuscinoses (NCLs) form a heterogeneous group of neurodegenerative lysosomal storage disorders. To date, the group consists of 13 genetically different disease entities, which are classified by the underlying gene mutation (CLN1-14) [1]. All NCL diseases except one (CLN4) are autosomal recessively inherited. Their shared clinical hallmarks encompass psychomotor regression, epilepsy and vision loss resulting in premature death [2][3][4]. An internationally agreed NCL disease nomenclature is based on both the underlying genetic defect as well as the phenotype [5]. Most NCL diseases have a most prevalent "classic" phenotype. However, due to the increasing implementation of next generation sequencing panels and exome sequencing as essential diagnostic tools for the assessment of rare diseases, more and more patients are identified with "non-classical" phenotypes caused by mutational effect that lead to varying loss of function of the associated protein. > Neuronal ceroid lipofuscinosis type 2 (CLN2; OMIM 204,500) is caused by mutations in the CLN2 gene resulting in deficient activity of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1) [6]. Patients with the classic late infantile phenotype present between ages 2 and 4 years with seizures and language developmental delay, followed by rapid deterioration of motor, language and cognitive skills over a 2-to 3-year period and premature death [7,8]. In patients with the classic late infantile CLN2 phenotype, seizures and psychomotor decline precede the vision loss [9]. Electroretinogram studies reveal subnormal or completely extinguished amplitudes as well as prolonged rod responses and severely subnormal cone b-wave responses [10]. Visual deterioration seems to occur after 3 years of age, although slight retinal abnormalities can be visible in presymptomatic patients in optical coherence tomography (OCT) imaging prior to obvious funduscopic changes. In OCT imaging, a bilateral symmetric progressive loss of central retinal thickness (CRT) could be shown especially between 4 and 6 years of age.

[18] Integrative human and murine multi-omics: Highlighting shared biomarkers in the neuronal ceroid lipofuscinoses.

  • Authors: N. Gammaldi, F. Pezzini, E. Michelucci, N. Di Giorgi, A. Simonati et al.
  • Year: 2023
  • Venue: Neurobiology of disease
  • URL: https://www.semanticscholar.org/paper/2c50113653b538549410afe59f69ce70a4184a43
  • DOI: 10.1016/j.nbd.2023.106349
  • PMID: 37952681
  • Citations: 3
  • Summary: The results offer promising targets for potential new therapeutic strategies and reinforce the hypothesis of a connection between NCLs and other forms of dementia, particularly Alzheimer's disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.483) > The collective term neuronal ceroid lipofuscinosis (NCL) refers to a group of inherited neurodegenerative disorders that affect children and young adults, and are characterized by retinopathy leading to blindness, ataxia and gait abnormalities, drug-resistant epilepsy, mental deterioration, and early death. The genetic landscape of NCL, also known as Batten disease, is highly heterogeneous with thirteen known disease forms to date (Table 1), associated with over 400 mutations in several genes entered in the NCL database (NCL resource mutation database, 2021). The NCLs are usually inherited according to an autosomal recessive pattern, although a rare, autosomal dominant adult-onset form has been identified (Mole et al., 2012). > The disease has a worldwide distribution with an incidence range calculated to be 1.28/100.000 live births, and there are about 6-700 new diagnoses each year. In around 9.7% of cases, however, mutations cannot be demonstrated in any of the known NCL genes in spite of a typical NCL clinical presentation (Santorelli et al., 2013;Simpson et al., 2014;Sleat et al., 2016). These cases remain molecularly undefined. > Cases are classified by: i) the age at disease onset (congenital, infantile, late infantile, juvenile, adult), ii) the designation of the mutated gene (CLN), iii) the characteristics of autofluorescent storage material accumulated in lysosomes and iv) the ultrastructural features of the cytosomes (Simonati and Williams, 2022). > No treatment other than palliative care is currently available for NCL (Iwan et al., 2021;Kohlschütter et al., 2019), with the exception of a cohort of patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease) undergoing enzyme replacement therapy (Brineura™, Cerliponase alfa) (Specchio et al., 2020). Poor information on disease pathophysiology, and therefore on possible disease biomarkers, is a major obstacle to clinical trials in this field.

[19] Mutations in the ATP13A2 Gene and Parkinsonism: A Preliminary Review

  • Authors: Xinglong Yang, Yan-ming Xu
  • Year: 2014
  • Venue: BioMed Research International
  • URL: https://www.semanticscholar.org/paper/b36b7be6ad6967929d150ff1d028173443266f48
  • DOI: 10.1155/2014/371256
  • PMID: 25197640
  • PMCID: 4147200
  • Citations: 59
  • Influential citations: 2
  • Summary: It is proposed that a single pathway whereby ATP13A2 mutations may contribute to NCLs and Parkinsonism is proposed, and how studies of mutations in this gene may provide new insights into PD pathogenesis and identify potential therapeutic targets is highlighted.
  • Evidence snippets:
  • Snippet 1 (score: 0.483) > ATP13A2 mutations have been identified not only in patients with Parkinsonism, but also in patients with neuronal ceroid lipofuscinoses (NCLs) [10]. NCLs are a group of neurodegenerative disorders that are also lysosomal storage diseases. Clinical manifestations are seizures, progressive cognitive and motor decline, and failing vision. The pathological hallmark of NCLs is accumulation of autofluorescent lipopigment within neuronal lysosomes [68]. > Recently, the mutation c.2429C>G in exon 22 of ATP13A2, predicted to result in the amino acid substitution p.Met810Arg, was identified in a Belgian family with NCLs [10]. Affected individuals showed not only typical NCL symptoms but also extrapyramidal involvement. Postmortem pathological examination revealed extensive lipofuscin deposits in the cortex, basal nuclei, cerebellum, and retina-but not the white matter-and electron microscopy showed whorled lamellar inclusions typical of NCLs [10]. A link between ATP13A2 mutations and NCL pathogenesis is further supported by studies in animal models [69,70]. In fact, mice deficient in ATP13A2 exhibited neuronal ceroid lipofuscinosis, -synuclein accumulation, and age-dependent sensorimotor deficits, suggesting that PD and NCLs share a pathogenic mechanism [71]. > A shared disease pathway may help explain earlier reports of individuals who demonstrate an "overlapping" neurodegenerative syndrome combining Parkinsonism and NCLs [72][73][74][75][76]. ATP13A2 is a lysosomal transport protein that helps maintain optimal pH in lysosomes [46], and ceramide is metabolized in lysosomes [77]. The apoptosis that appears to cause NCLs is associated with increased levels of ceramide [78,79], which have also been linked to -synuclein deposition, which may contribute to PD pathogenesis [80].

[20] S-Palmitoylation of Synaptic Proteins in Neuronal Plasticity in Normal and Pathological Brains

  • Authors: A. Buszka, Agata Pytyś, Domnic Colvin, J. Włodarczyk, T. Wójtowicz
  • Year: 2023
  • Venue: Cells
  • URL: https://www.semanticscholar.org/paper/e804de43357e439c5aa0f43b76899084f5414b6c
  • DOI: 10.3390/cells12030387
  • PMID: 36766729
  • PMCID: 9913408
  • Citations: 32
  • Influential citations: 1
  • Summary: Experimental work devoted to understanding the impact of protein palmitoylation on functional changes in the excitatory and inhibitory synapses associated with neuronal activity and neuronal plasticity are discussed.
  • Evidence snippets:
  • Snippet 1 (score: 0.482) > The neuronal ceroid lipofuscinoses (NCLs) (also known as Batten disease) are a class of inherited nervous system disorders associated with mutations in 13 genes (CLN1 to CLN14) that most often begin in childhood and interfere with a cell's ability to recycle a cellular residue called lipofuscin [231]. NCL-associated proteins are localized to lysosomes, endoplasmic reticulum, and other cellular locations; but CLN gene mutations lead primarily to dysfunction in lysosomes. One class of diseases called infantile neuronal ceroid lipofuscinosis (CLN1 disease) is caused by a mutation in CLN1, which encodes palmitoyl-protein thioesterase 1 (PPT1) [223] and may have several phenotypes and types of symptom progressions [232]. In the infantile form, difficulties in acquiring skills such as standing, walking, and talking occur between 6-12 months, and may progress with age into vision loss, seizures, psychomotor deterioration, and premature death [233]. > The molecular mechanism explaining how PPT1-deficiency may affect cell physiology was studied in various systems. In Drosophila, loss of PPT1 causes defects in endocytic trafficking [234] and exocytosis and endocytosis of synaptic vesicles [235]. In mice, PPT1 knockout resulted in reduced expression of presynaptic proteins (e.g., SNAP25), a smaller number of synaptic vesicles, and abnormal expression of NMDAR, contributing to excitotoxicity [223]. PPT1 deficiency caused persistent membrane anchorage of the palmitoylated SV proteins, which hindered the recycling of the vesicle components that normally fuse with the presynaptic plasma membrane during SV exocytosis both in postmortem brain tissues from patients and in brain tissues from PPT1 knockout mice [211]. Altogether, loss of PPT1 in infantile ceroid lipofuscinosis may result in degeneration of excitatory and inhibitory cells and impaired synaptic transmission [223,236].

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.